Login
Oncologisch onderzoek.nl
Home
Login
Links
Contact
Registreren
Jarig
Nieuws
<<
<
1
5
10
50
100
497
498
499
500
501
502
503
>
>>
Pagina 500/ 591 - 15 Lijnen per pagina - 8858 Lijnen in deze sectie
Titel
Commentaren
Datum
Auteur
<<
<
1
5
10
50
100
497
498
499
500
501
502
503
>
>>
Pagina 500/ 591 - 15 Lijnen per pagina - 8858 Lijnen in deze sectie
Tags
'gunstig hoog-risico'
“one thousand HER2 patients” project
[11C] docetaxel
[18F]paclitaxel
%FT
10-year recurrence
15-hydroxyprostaglandinedehydrogenase
15-PGDH
16K PRIL
16q23
1703-studie
18F-FDG opname
1990 to 2017
1997-2016
1p 19q co-deleted oligodendroglioma
1p 19q codeleted oligodendroglioma
21-gen recurrence score assay
21-gene expression assay
21-gene recurrence score
25-hydroxyvitamin D
25-OH-D level at time of diagnosis
27-hydroxycholesterol
28-year risk of lung cancer
3 vs. 6 months oxaliplatin-based adjuvant chemotherapy
321GO
3D brachytherapy
3DCRT
4EVER trial
4L lymph node dissection
5-ARIs
5-FU
5α-reductase inhibitors
6-MP plus methotrexate
70-GS
8-OHdG
90101 CREATE-studie
90YIT
91-maands update van CALGB 100104-studie
A.R.R.O.W-studie
A041202 study
AAC
AACR
AACR 2015
AACR Academy
AAML0531 trial
AAP
ABCSG 8A trial
ABCSG-18 study
abdominal and gluteofemoral size
abdominal radiation for childhood cancer; subsequent risk of diabetes
abemaciclib
abemaciclib plus fulvestrant for MBC
Abi Race studie
abirateron
abiraterone
abiraterone for prostate cancer
ablatieve behandeling
abnormale peritoneale cytologie
ABOUND.2L+ study
ABSI
ABSOLUTE
absolute dense area
absoluut neutrofielgetal
ABT-199
ABTC
ABVD
ACC
accelerated partial breast irradiation
ACCRU study SC-1603
accrual
ACE
ACE study
ACE-LY-004 studie
ACES
acetaminophen
ACHIEVE study
acne
ACOSOG Z0011
ACP statement
acquired resistance to osimertinib
acraal melanoom
ACRIN 6686-studie
AcSé phase 2 study
ACT
Act.In.Sarc study
actieve surveillance
ACTIM
actinisch carcinoom
active melanoma brain metastases
active surveillance
active surveillance for prostate cancer
activering immuunsysteem
ACTs
acupuncture for aromatase inhibitor-related joint pain
acute cancer-associated venous thromboembolism
acute care use after initiation of systemic cancer therapy
acute GVHD
acute kidney injury
acute leukemie
acute lymfoblastische leukemie
acute lymphoblastic leukemia
acute myeloid leukemia
acute myeloïde leukemie
acute promyelocytische leukemie
acute promyeolcytische leukemie
acute toxicity
AD-risico
ADAM-studie
ADAM8
ADAMTS-mutaties
ADAPT-studie
adaptive immune resistance
adaptive randomization
adavosertib
ADC as response marker
ADC versus SCC
ADCs
adding OFS to tamoxifen
addition of chemotherapy to neoadjuvant radiotherapy
additional cytogenetic abnormalities
ADEBAR
ademanalyse
ademtest
adenocarcinoma of the small intestine
adenocarcinoom
adenoma detection rate
ADH
adherence
adherene to adjuvant endocrine therapy
adherentie
adherentie AET
adherentie orale chemotherapie
adipose tissue distribution
adipositas
adiposity and survival
adjuvant aspirin for cancer
adjuvant bevacizumab
adjuvant capecitabine
adjuvant care
adjuvant chemotherapy
adjuvant chemotherapy for breast cancer
adjuvant chemotherapy regimens
adjuvant CRT
adjuvant denosumab
adjuvant erlotinib for early-stage NSCLC
adjuvant FOLFIRINOX versus gemcitabine
adjuvant imatinib
adjuvant ipilimumab
adjuvant multimodality therapy
adjuvant radiation therapy
adjuvant radiotherapy
adjuvant RT
adjuvant S-1
adjuvant S-1 with or without docetaxel
adjuvant therapy
adjuvant trastuzumab
adjuvant trastuzumab duration
adjuvant trastuzumab for HER2-positive breast cancer
adjuvant treatment
adjuvant versus salvage radiotherapy
ADJUVANT-studie
adjuvante chemotherapie
adjuvante CRT
adjuvante HER2-remming
adjuvante hormoontherapie
adjuvante systemische therapie
ADMIRAL study
ADMIRAL trial
ADNEX
ado-trastuzumab emtansine
adolescent and young adult
adolescent and young adult HL
adolescent overweigh or obesity
adolescents and young adults
adoptive T-cell therapy
ADORE trial
ADR
adrenocortical carcinoma
ADT
ADT risk of depression
adult cancers
adult height
adult survivors of childhood ALL
adult survivors of childhood cancer
adult T-cell leukemia lymphoma
adult type granulosa cell tumors of the ovary
adult weight gain
advanced adrenocortical carcinoma
advanced anal squamous cell carcinoma
advanced biliary tract cancer
advanced biliary tract cancers
advanced breast cancer
advanced cancer
advanced EGFR-positive non-squamous NSCLC
advanced endometrial cancer
advanced esophageal cancer
advanced esophagogastric cancer
advanced extraskeletal myxoid chondrosarcoma
advanced gastric cancer
advanced gastroesophageal cancer
advanced gastrointestinal cancer
advanced germ cell tumors
advanced HCC
advanced hepatocellular carcinoma
advanced HN CSCC
advanced HNSCC
advanced Hodgkin lymphoma
advanced indolent lymphoma
advanced leiomyosarcoma liposarcoma
advanced lung cancer
advanced melanoma
advanced Merkel cell carcinoma
advanced mucosal melanoma
advanced non-clear cell RCC
advanced non-clear-cell RCC
advanced non-small cell lung cancer
advanced NSCLC
advanced NSCLC in special populations
advanced or metaastatic colorectal cancer
advanced or metastatic colorectal cancer
advanced or recurrent endometrioid endometrial cancer
advanced or refractory desmoid tumors
advanced ovarian cancer
advanced ovarian carcinoma
advanced ovarium neoplasms
advanced pancreatic cancer
advanced papillary renal cell carcinoma
advanced PDAC
advanced prostate cancer
advanced pulmonary sarcomatoid carcinoma
advanced RCC
advanced recurrent ovarian cancer
advanced refractory esophageal squamous cell carcinoma
advanced renal cell carcinoma
advanced sarcoma
advanced solid cancers
advanced solid malignancies
advanced solid tumors
advanced squamous NSCLC
advanced systemic mastocytosis
advanced thymoma
advanced triple-negative breast cancer
advanced UC
advanced urothelial cancer
advanced wild-type BRAF melanoma
advanced-stage cancer
advanced-stage Hodgkin’s lymphoma
Adventist cohort compared with a US Census popiulation
adverse events
adverse mental health outcomes
aerobe inspanning
aerobic and resistance exercise
aerobic exercise during chemotherapy
afatinib
afatinib versus methotrexaat
AFFIRM
AFFIRM-studie
aflibercept
AFUGEM GERCOR
AGC
age
age at diagnosis
age at diagnosis of colorectal cancer
age disparities
age-specific BMI
agent orange
AGES-Reykjavik study
aggressive lymphoma
AGITG MAX study
AGO-OVAR 16-studie
agressieve fibromatose
agressive squamous cell carcinoma
AGRICAN-studie
aGVHD
aHCC
AHEP0731 study
AHL2011 study
AHOD1221 study
AI
AI-therapie
AIC
AIO-FLOT3 studie
AJCC CSM-8
AL amyloidosis
AL-amyloïdose
ALBI
ALCANZA-studie
ALCL
alcohol
alcohol and tobacco consumption
alcohol consumption
alcohol intake
alcoholconsumptie
alcoholgebruik
ALCYONE-studie
aldoxorubicine
alectinib
alectinib for crizotinib-resistant ALK-positive NSCLC
alectinib versus crizotinib
ALEX study
ALEX study PRO analysis
ALEX-studie
ALFA-0701 trial
ALiCCS studie
ALiCCS study
ALiCCS-studie
alisertib
ALK-positive non-small cell lung cancer
ALK-positive NSCLC
ALK-rearranged NSCLC
ALK-remmer
ALK1
alkaline phosphatase
alkylerende chemotherapie
ALL
Alliance A091401-studie
Alliance N0572-studie
ALLIVE-studie
allo-BMT
allo-HSCT
allo-HST
allogene hematopoïetische stamceltransplantatie
allogene stamceltransplantatie
allogeneic BMT in childhood
allogeneic hematopietic cell transplantation
allogeneic hematopoietic cell transplant
allogeneic hematopoietic cell transplantation
allogeneic HSCT
alloHCT
alloHSCT
alloSCT
ALND
alopecie
alpelisib
alpelisib plus fulvestrant
alpha-fetoprotein
ALTA-1L
ALTA-studie
ALTER 0303 study
ALTERNATIVE-studie
ALUR-studie
alveolar soft-part sarcoma
alvleesklierkanker
AM
Amara West
AMD
American Association for Cancer Research
American Cancer Society richtljnen
AMG 337
AMH
AML
AML in elderly nonfit patients
AML MDS
AML MDS in older patients
AML or high-risk MDS
AML with internal tandem duplication of Fms-like tyrosine kinase 3
AML-relapse after allo-HCT
AML-risico
AML17-studie
AMPK variant
AMPK-route
AMPLE-2 study
amrubicine
analgesic use
analgesics
analgetica
analyse AZURE-studie
analyse binnen PICCOLO-studie
analyse CheckMate 205-studie
analyse COG AAML 1031
analyse CROSS-studie
analyse fase 3-studie CALGB 40503
analyse fase 3-studie GeparQuinto
analyse MA.27-studie
analyse NORDIC-VII studie
analyse STAMPEDE-studie
Analyse van CheckMate 066 en CheckMate 067
analyse van fase 3-studie CAO ARO AIO-04
analyse van STAMPEDE-studie
anamorelin
anaplastic large-cell lymphoma
anaplastisch grootcellig lymfoom
anaplastisch schildkliercarcinoom
anastrozol
anastrozole
and HIV infection
and rituximab
and time already survived
androgeendeprivatie
androgeenreceptor
androgeensuppressie
androgen concentrations in prepubertal girls
androgen deprivation therapy
androgen deprivation therapy for prostate cancer
androgen receptor expression
androgen receptor signaling inhibitor
anesthesia
aneuploïdie
angiogenese
angiosarcomen
angiosarcoom
angiotensin converting enzyme inhibitors
ANGPT2
ANGPT2 and NOS3 polymorphisms
animal and plant protein intake
anlotinib
anlotinib versus sunitinib
anoikis-resistentie
anorexia nervosa
anorexie
anosmin-1
aNSCLC
antacida
anthracycline chemotherapie
anthracyclines
anthracylcines
anti-angiogene middelen
anti-angiogenese
anti-CD19 and anti-BCMA CAR T-cells
anti-CTLA-4 plus anti-PD-1 blockade
anti-Hu
anti-humaan T-lymfocyt immunoglobuline
anti-PD-(L)1 therapy
anti-PD-1 antibodies plus RT
anti-PD-1 L1
anti-PD-1 monotherapy
anti-PD-1 related pneumonitis
anti-PD-1 therapy
anti-PD-1 therapy for advanced melanoma
Anti-T-lymfocten globuline
anti-thymocyte globulin
anti-VEGF therapie
anti-VGEF therapie
antiangiogenese
antibiotics
antibodies
antibody-drug-conjugates
anticoagulants and breast cancer survival
anticoagulatie
antihypertensive drugs
antiogeneseresistentie
antioxidant supplements
antioxidanten
antioxidants
antithymocytenglobuline
antitumor-werkzaamheid van bisfosfonaten
antiviral treatment
anus squameus celcarcinoom
anuscarcinoom
anuskanker
AO AOA
apalutamide
apatinib
apatinib after failure of chemotherapy
apatinib plus oral etoposide
aPC
APHINITY-studie
API-AI
apixaban
APL
apoptose
appendixcarcinoom
aprepitant
APT trial
AR expression in breast cancer
AR-expression
AR-remming
AR-V7
ARAMIS study
ARCAD
ARCAGE-studie
aRCC
ARCHER 1050
ARCHER 1050-studie
ARCHES study
ARIC-studie
ARIEL3-studie
Aristotle study
ARMD
aRMS
aromatase inhibitors
aromatase inibitor-induced adverse effects
aromataseremmer
aromataseremmers
array comparative genomic hybridization
ARROW study
ARRY-380
arseentrioxide
arsenicum
ART
ART-gerichte behandeling
arterial thromboembolism preceding cancer diagnosis
artificial intelligence
ARTIS study
ARTIST 2 study
artralgie
ARv567es
AS04-adjuvanted HPV-16 18 vaccine
ASCC
ASCEND-2
ASCEND-3 final results
ASCEND-5
ASCEND-5 studie
ascites
ASCO
ASCO 2016
ASCT
ASCT versus maintenance chemotherapy consolidation
ASH 2015
Ashkenazi Jewish ancestry
ASILs
asparaginase-associated pancreatitis
ASPECCT
AspECT study
ASPIRE-studie
aspirin
aspirin NSAID use
aspirin use
aspirine
aspirine NSAIDs
aspirineprofylaxe
ASPS
assessment of lung cancer risk
Assisted reproduction
assisted reproductive technology
associatie diabetes en kanker
association between PFS and QOL
association of age with efficacy of immunotherapy
association of cutaneous toxic effects with outcomes
association of depression and anxiety with mortality
association of PD-L1 expression status with efficacy of PD-1 PD-L1 inhibitors
association of use of PET-CT with mortality
association with lung cancer risk
association with other types of tumors
association with survival
AST
astma
ASTRO 2015
ASTRO 2016
asunercept
asymptomatic brain metastases
asymptomatic WM
ATBC Study
ATC
ATE
atezolizumab
atezolizumab plus bevacizumab
atezolizumab plus nab-paclitaxel
ATL
ATLANTIC-studie
ATM
ATOM trial
atopie
ATR-blockers
atrial fibrillation
atriumfibrilleren
ATRTs
ATTRACTION-2 studie
ATTRACTION-3 study
atypical bronchopulmonary carcinoids
atypical squamous cell of undetermined signifance
atypical squamous cells of undetermined significance
atypisch meningioom
atypische ductale hyperplasie
atypische hyperplasie
Atypische teratoïde rhabdoïde tumor
atypische teratoïde rhabdoïde tumoren
AUGMENT study
AURA
AURA-studie
AURA-substudie
AURA2
AURA3
AURA3 study
AURA3-studie
AURELIA
AURELIA-studie
AURELIA-substudie
Aurora A
aurora kinase A inhibition
Australian Melanoma Family Study
auto-immuunziekten
autofagie
autoHCT
autoHSCT
autoimmune disease
autologe stamceltransplantatie
autologous stem cell transplantation
AVAglio
AVAST-M study
AVAST-M trial
avastin
avelumab
avelumab plus axitinib
AVERT study
AVERT trial
axicabtagene ciloleucel
axillaire lymfeklierdissectie
axillaire radiotherapie
axillaire status
axillaire ultrasound
axillary dissection
axitinib
axitinib plus pembrolizumab
AYA cancer
AYA cancer survivors
AYA-maligniteiten
AYAs
AYAs versus older adults
AZ9291
azacitidine
B-cel activering
B-cel lymfoom
B-cel maligniteiten
B-cel precursor-ALL
B-cell malignancies
B-cellymfoom
B-precursos ALL
B-progenitor acute lymphoblastic leukemia
baarmoederhalskanker
BALLET-studie
bariatric surgery
bariatrische chirurgie
Barrett esophagus
Barrett slokdarm
Barrett-slokdarm
Barrett's esophagus
Barrett's slokdarm
Barrett’s oesophagus
basaalcelcarcinoom
basal-like mammacarcinoom
Baselga
bassi
BAT
bb2121
BBB
BBD
BBD-BC
BCBM
BCC
BCCs
BCCSS
BCG
BCG vaccination in childhood
BCIN+
BCIS
Bcl-2
BCL2 expression
BCNU
BCP-ALL
BCS
BCS for N2 N3 disease
BCT versus mastectomie
BCT vs MAST
BEACON CRC study
BEACON-studie subgroep-analyse
BEAT Cancer interventie
BEBYP-studie
beeld-geleide brachytherapie
beeldvorming
beenmergevaluatie
beha
belangenconflicten
belinostat
BELLE-2 studie
BELOB
bendamustine
benign biopsy rate
benign ovarian tumor
benign solid tumors
benigne borstziekte
benzeen
benzodiazepine
BEP
BERIL-1
bestraling
beta-arrestin-1
BETA-Text
bètablokkers
between-hospital variation
bevaciumzab
bevacizumab
bevacizumab biosimilar
bevacizumab preconditionering voor chemotherapie
BEVZ92
BFORE-studie
BGJ398
bhatia
BI-ALCL
BIA ALCL
BIDOC-studie
BIG 1-01
BIG 1-98
bijnierschorscarcinoom
bijniertumoren
bijwerkingen
bilateral breast cancer
bilaterale risicoreducerende mastectomie
BILCAP study
BILCAP-studie
biliary tract cancer
BIND-014
Bing-Neel syndrome
binimetinib
biochemical recurrence of prostate cancer
biochemisch recidief
biological aging
biologische beschikbaarheid
biomarker
biomarker voor respons op bevacizumab
biomarkeranalyse ASPECCT-studie
biomarkers
biopsie schildwachtklier
BIRC3 mutations
BIRCH-studie
birinapant
birth defects
birth order
bisfosfonaat
bisfosfonaten
blaascarcinoom
blaaskanker
black race
black versus nonblack men
black versus white women
Black Women's Health Study
Black Women’s Health Study
bladder cancer
bladder cancer in postmenopausal women
bladder cancer VI-RADS score
BLC2001 study
bleeding after ACS
bleeding risk
bleomycin-related pulmonary toxicity
bleomycine
blinatumomab
blinded double reading
bloedgluocse
bloeding
bloedkanker
bloedlipiden
bloedtest colorectaalcarcinoom
blood arsenic levels
blood cholesterol
Blood or Marrow Transplant Survivor Study-2
blood pressure
blood tests
blood triglycerides
blood tumor mutational burden
bloodstream infections
BLOOM study
BLU-667
BM
BMD
BMI
BMM
BMT CTN 1501 study
BO
body composition
body composition and cardiovascular events
body fat
body fat distribution
body fat mass
body fat percentage
body mass index
body shape trajectory
Boekel
BOLERO-1
BOLERO-2
bone loss in younger breast cancer patients
bone marrow biopsy
bone marrow plasma cell level
bone metabolism
bone metastases
bone-only metastasis
bone-targeted agents
borderline ovariumtumor
borderline resectable pancreatic cancer
Borealis-1 studie
Borealis-2 studie
borstbiopsie
borstchirurgie
borstdichtheid
borstimplantaat
borstkanker
borstkanker bij mannen
borstkankerpreventie
borstkankerscreening
borstkankerscreening oudere vrouwen
borstkankersterfte
borstparende chirurgie
borstreconstructie
borstreconstructie na mastectomie
borstsparende chirurgie
borsttomosynthese
borstvoeding
bortezomib
bortezomib plus chemotherapy
bortezomib plus rituximab maintenance
BOSS cohort
bot-SPNs
boteffect
botmetastasen
botmetastasen van mammacarcinoom
botmetastasering
botmicrometastasen
botox
botpijn
botsarcoom
bovenste-luchtwegkanker
BP-RMS
BPDCN
BPH
BPM
BPs
BR
BRAC1 2-mutation
brachytherapie
brachytherapy for glioblastoma
BRAF
BRAF 594 en 596 mutaties
BRAF 600 wild type melanoom
BRAF mutation
BRAF non-V600-mutant mCRC
BRAF plus MEK inhibition
BRAF plus MEK inhibitors
BRAF V600-mutated mNSCLC
BRAF V600-mutated NSCLC
BRAF V600E
BRAF V600E mCRC
BRAF V600E-mutated CRC
BRAF wild-type advanced melanoma
BRAF-genfusies
BRAF-mutant melanoma
BRAF-mutated malignancies
BRAF-mutated melanoma
BRAF-remmer
BRAF-remmers
BRAF-remming
BRAF-V600E
brain imaging
brain metastases
brain metastases nivolumab plus ipilimumab
brain metastasis
brain tumors
brain volume
brain-metastatic lung cancer
BRCA
BRCA mutation carriers with breast cancer
BRCA-defective tumors
BRCA-mutatie
BRCA-related cancer
BRCA1
BRCA1 2 germline mutations
BRCA1 2 mutation
BRCA1 2 mutation carriers
BRCA1 2 mutations
BRCA1 2 variants
BRCA1 2-mutatie
BRCA1 2-mutaties
BRCA1 2-mutations
BRCA1 2-negative Chinese breast cancer patients
BRCA1 and BRCA2 mutations
BRCA1 mutation
BRCA1-mutatie
BRCA2
BRCA2-associated breast cancer
BRCA2-mutaties
breast and lung cancer mortality in women
breast and prostate cancer
breast angiosarcoma
breast cancer
breast cancer and other cancers
breast cancer bone metastasis
breast cancer brain metastases
breast cancer brain metastasis
breast cancer chemotherapy
breast cancer diagnosis
breast cancer family history
breast cancer in childhood cancer survivors
breast cancer in high-risk women
breast cancer in young women
breast cancer leptomeningeal disease
breast cancer metastases
breast cancer metastatic recurrence
breast cancer molecular subtypes
breast cancer mortality
breast cancer mortality by comorbidty and age
breast cancer outcomes
breast cancer ovarium cancer predisposition genes
breast cancer patients
breast cancer recurrence
breast cancer risk
breast cancer screening
breast cancer screening in average-risk women
breast cancer subtype
breast cancer subtypes
breast cancer surgery
breast cancer survival
breast cancer survivors
breast cancer survivorship
breast cancer-related fatigue
breast cancer-specific mortality
breast compression
breast desmoid tumor management in France
breast intraepithelial neoplasia recurrence
breast milk paclitaxel excretion
breast symptoms
breast-conserving surgery
breast-conserving therapy
brentuximab vedotin
brentuximab verdotin
brigatinib
BRIM-3 studie
BRIM7 study
BRIM8-studie
British Childhood Cancer Survivor Study
Broad-based genomic sequencing
BRPC
BRRM
bruton's tyrosine kinase
BTC
BTK
BTK inhibition
Burkitt's lymfoom
busulfan plus fludarabine
busulfan plus melphalan conditioning
BV
BV plus AVD
BVD-523
C SCANS studie
C-486
C-ALCL
C-ETACs as hallmarks of cancer
C-ion RT
C-reactive protein
C-TASK FORCE studie
CA-125
CA180-226 studie
CA19-9
CA209-003 studie
CA209-003 trial
CA301 study
CABARET-studie
cabazitaxel
cabazitaxel plus carboplatin
CABOSUN
cabozantinib
cabozantinib versus everolimus
cachexia
CAD
CADC
CADM1 MAL-methylering
cafeïne
caffeïne
CAG-repeat
CAIRO3
calcitonin receptor-like
calcium
calcium and magnesium intake
calcium supplementation
calciuminname
calculated tumor area
CALGB 50604
CALGB 89803-studie
CALGB Alliance 140503
CALGB SWOG 80405 study
CALOR-studie
caloric restriction
CAM
camrelizumab
cancer
cancer burden in patients with sleep apnea
cancer clinical trial participants
cancer detection rate
cancer diagnosis
cancer diagnosis in primary care
cancer driver genes
cancer drugs approved based on response rate
cancer history
cancer in solid organ transplantation recipients
cancer incidence and mortality
cancer mortality
Cancer of unknown rimary
cancer outcomes
cancer patients
cancer patients treated with anticoagulation
cancer prevention
cancer recurrence
cancer risk
cancer risk after hematuria diagnosis
cancer risk in children
cancer risk in children and adolescents
cancer screening
cancer screening in people with mental illness
cancer surgical procedures
cancer survivors
cancer susceptibility genes
cancer-related cognitive impairment
cancer-related fatigue
cancer-specific mortality
cancer-testis antigens
CANDOR study
canine lung cancer detection
cannabigerol
cannabis
CanSNET-studie
CANTO trial
CAO ARO AIO-04 study
CAP-studie
capecitabine
capecitabine versus observation
capivasertib for tumors with AKT mutations
CAPP-Seq
CAPRI-GOIM
CAPRICE
CAR T-cell therapy
CAR T-cellen voor solide tumoren
CAR T-celtherapie
CAR-T celtherapie
CAR19 22 T-cell therapy
carbazitaxel
carbon ion RT
carboplatin with radiotherapy
carboplatine
carcinoïd tumoren
CARD study
cardiac events
cardiac safety
cardiale disfunctie
cardiale toxiciteit
cardiale veiligheid
cardiopulmonary complications
cardiorespiratorische fitheid
cardiorespiratory fitness
cardiotoxiciteit
cardiotoxiciteit anthracylines
cardiotoxiciteit chemotherapie
cardiotoxicity
cardiovasculair risico
cardiovasculaire toxiciteit
cardiovascular adverse events
cardiovascular disease risk
cardiovascular diseasse
cardiovascular risk
cardiovascular toxicity
carfilzomib
carfilzomib for myeloma
CARMENA study
CARMENA-studie
carmustine
Carolina Breast Cancer Study
carotenoïden
carpaal-tunnelsyndroom
CARTS study
CASPIAN study
CASPS study
CASR
CASSINI study
CASSIOPEIA study
CASTOR and POLLUX age subgroup analysis
castratieresistent prostaatcarcinoom
castration-resistant prostate cancer
CATCH
catch-up HPV-vaccination
CATNON-studie
catumaxomab
cause of death
cause-specific mortality
CBC
CBC risk
CBC-risico
CBTRUS
CBTS
cc mRCC
CC-223
CC-486
CCEC
CCNE1 expression
CCR7
ccRCC
ccRCC brain metastases
CCRT
CCSS
CD103+ immune cells
CD19 CAR-T cell therapy
CD4
CD4+ percentage
CD45-targeted antibody-radionuclide conjugate
CD47 blockade plus rituximab
CD8+ T cell infiltration
CDG
CDK4 6 inhibitor plus AI
CDK4 6 inhibitors
CDK4 6-remming
CDKN2C
CDS
CDX-110
CDX2
CEA
CEA-specifieke T-cel respons
cediranib
CEGT
celecoxib
CELESTIAL trial
cell nest size
cell-free urine
cellulaire immuuntherapie
cellular immune activation
CelTIL-score
celvrij circulerend tumor DNA
central adiposity
centrale adipositas
cerebellopontine angle tumors
cerebrospinal fluid microRNA signatures
cerebrospinale vloeistof
ceritinib
cervical cancer
cervical cancer screening
cervical HPV-testing
cervical neoplasia
cervical screening
cervicale glandulaire neoplasie
cervicale intra-epitheliale neoplasie graad 3
cervicale intraepitheliale neoplasie
cervicale-slokdarmkanker
cervixcarcinoom
cervixcarcinoomscreening
cervixconisatie
cervixkanker
cervixkankerscreening
cervixlaesies
CESM
CeTeG NOA-09 study
CETSA
cetuximab
cetuximab-IRDye800
cetuximab-related infusion reactions
cetuximab-resistentie
CF-WBI
cfDNA
cfDNA genotyping
CGC
cGVHD
ch
CHAARTED-analyse
CHAARTED-studie
change in serum uric acid level
change of breast cancer subtype during neoadjuvant chemotherapy
Charlson-score
CHD
CheckMate 012
CheckMate 016-studie
CheckMate 017 en 057
CheckMate 017 en CheckMate 057
CheckMate 017-studie
CheckMate 025
CheckMate 026-studie
CheckMate 032 study
CheckMate 037
CheckMate 040
CheckMate 064
CheckMate 066
CheckMate 066 study
CheckMate 067
CheckMate 067 five-year survival
CheckMate 069
CheckMate 069 066 en 067
CheckMate 141
CheckMate 141-studie
CheckMate 142
CheckMate 204 study
CheckMate 205 study
CheckMate 214
CheckMate 214 study
CheckMate 227 study
CheckMate 227-studie
CheckMate 238-studie
CheckMate 275
CheckMate 358 trial
CheckMate 370-studie
CheckMate 384 study
CheckMate 436 study
CheckMate 511 trial
CheckMate 568
CheckMate 817
CheckMate-032 study
CheckMate-142
checkpoint blockade immunotherapy
checkpoint inhibitor therapy
checkpoint kinases
CHEK2 1100delC
CHEK2 germline pathogenic variants
CHEK2-mutaties
CHEK2*1100delC
chemerin plasma concentration
chemobrain
chemoimmunotherapy
chemopreventie mammacarcinoom
chemopreventie van mammacarcinoom
chemoprevention with low-dose aspirin
chemoradiotherapie
chemoradiotherapy
chemoradiotherapy versus radiotherapy
chemorefractory metastatic colorectal cancer
Chemoresistentie
chemosensitizatie
chemotherapie
chemotherapie tijdens zwangerschap
chemotherapie-geïnduceerd ovariumfalen
chemotherapie-geïnduceerd POF
chemotherapie-geïnduceerde febriele neutropenie
chemotherapie-geïnduceerde misselijkheid en braken
chemotherapy
chemotherapy adherence
chemotherapy after colorectal cancer liver metastasectomy
chemotherapy alone versus combined modality therapy
chemotherapy benefit
chemotherapy demands
chemotherapy for childhood cancer
chemotherapy free treatment
chemotherapy plus immunotherapy
chemotherapy plus ponatinib
chemotherapy regimens
chemotherapy response
chemotherapy response score
chemotherapy versus observation
chemotherapy with bevacizumab or temsirolimus
chemotherapy with versus without bevacizumab
chemotherapy-free treatment
chemotherapy-induced cardiotoxicity
chemotherapy-induced nausea and vomiting
chemotherapy-induced peripheral neuropathy
chemotherapy-induced thrombocytopenia
chemotherapy-related cognitive impairment
chemotherapy-related hematological toxicity
CHF
CHHiP-studie
childbearing potential
childbirth
childhood ALL
childhood B-ALL
childhood brain tumors
childhood cancer
childhood cancer survival in immigrants
Childhood Cancer Survivor Study
childhood cancer survivors
childhood leukemia
childhood leukemia and lymphoma survivors
childhood leukemia risk
childhood leukemia; maternal hormonal contraception use
childhood nasopharyngeal carcinoma
children
children and AYAs with cancer
children with cancer
Children’s Oncology Group
Children’s Oncology Group study
Children’s Oncology Group Study AALL03N1
chimeric antigen receptor
Chinese Alliance for Research in Thymomas database
CHIP
chirurgie
cHL
cHL in young patients
cholangiocarcinoma
cholangiocarcinoom
cholecystitis
chondrosarcoma
chondrosarcoom
CHOP
chordoma
chordoom
chromische lymfocytische leukemie
chromocolonoscopy versus white-light colonoscopy
chromosoom 21
chromosoominstabiliteit
chromothripisis
chronic health conditions
chronic lymphocytic leukemia
chronic pain
chronic phase CML
chronisch graft-versus-host disease
chronische fase CML
Chronische fase-CML
chronische lymfatische leukemie
chronische lymfocytische leukemie
chronische lymfoide leukemie
chronische myelomonocytische leukemie
Chronos-1
chubb
chyleuze ascites
CIA
cigarette type
cilengitide
CIMP
CIN
CIN 3
CIN2 3
CIN2+ detection
CINP
CINV
CIO
CIOD
CIPN
circadiaan ritme
circulating DNA
circulating HPV DNA
circulating levels of specific lipid groups
circulating sex hormone levels
circulating tumor cells
circulating tumor DNA
circulerend DNA
circulerend tumor-DNA
circulerende tumorcellen
circulerende tumorcellen; detectie nieuwe mutaties
circulerende vetzuren
CIRT
CISIG
cisplatin
cisplatine
CITN-10 study
citrusfruit
cixutumumab
CLARITY study
claudine 18.2
CLEAR
clear cell renal cell carcinoma
Clevers
clinical and genomic risk
clinical characteristics and outcomes
clinical features for prediction of survival
clinical meaningful outcomes
clinical trial enrollment
clinical trial participation
clinical trials
clinically N2 non-small cell lung cancer
clinicogenomic classifier
CLL
CLL 2007 SA-studie
CLL in younger patients
CLL SLL
CLL with coexisting conditions
CLL-IPI
CLL10
CLL2-BAG study
CLLM1-studie
CLM
CLND
clofarabine
clofarabine plus total body irradiation conditioning
CLOG1302-studie
clomid
clomifeen
clomifeencitraat
Clozel
CME
CML
CML-BP
CML-CP
CML-studie IV
CMM
CMML
CMS risk
CMSs
CMV-viremie
CN-AML
CNAs
CNBSS
CNS efficacy
CNS metastases
CNS metastasis
CNS NGGCTs
CNS response
CNS-DLBCL
CNS-lymfoom
CNS-metastasen
CNS-recidief HER2-tumoren
CNS-tumoren
CNS-tumoren; impact van behandelcentrum
cobas
cobimetinib
COBRA study
COBRA-score
coBRIM-studie
cochlear radiation dose
coffee intake
COG AALL0434
COG AALL0622-studie
COG AALL1331 study
COG AAML0631-studie
COG ARAR0331 study
COG AREN0533-studie
COG-studie AAML0531
COG-studie AREN0532
cognitief functioneren
cognitieve disfunctie
cognitieve klachten
cognitieve veranderingen na chemotherapie
cognition
cognitive and neurobehavioral impairment
cognitive performance
colectomie
collider stratification bias
COLOFOL-studie
Cologuard
colon cancer
colon cancer drug metabolism
Colon Cancer Family Registry
colon cancer peritoneal recurrence
colon cancer risk
colon-NET
coloncarcinogenese
coloncarcinoom
colonkanker
colonoscopie
colonoscopy-based CRC screening
colorectaakanker
colorectaaladenomen
colorectaaladenoom
colorectaalcarcinoom
colorectaalkanker
colorectaalkankerscreening
colorectaalneoplasie
colorectaalpoliepen
colorectal
colorectal adenomas
colorectal cancer
colorectal cancer molecular subtypes
colorectal cancer mortality
colorectal cancer precursors
colorectal cancer screening
colorectal carcinogenesis
colorectal liver metastases
colorectale chirurgie
colorectale levermetastasen
colorectale neoplasie
coloscopie
COLUMBUS trial
COMBI-AD studie
COMBI-AD study
COMBI-d studie
COMBI-MB studie
COMBI-v
CombiDT
combination of HAI and systemic chemotherapy
combined analysis of N9831 and NSABP B-31
combined BRAF- and MEK-inhibition plus PD-1 blockade
combined CTLA-4 and PD-1 inhibition
combined effect of breast density and BMI
combined modality treatment
combined nivolumab and bevacizumab
combined PD-1 blockade and VEGF inhibition
combined-modality therapy
commercial gene expression tests
community jury
comorbiditeiten
comorbidities
comparative safety of ICIs
comparison Hong Kong and USA
comparison of first-line treatments
comparison of five guidlelines
complementaire en alternatieve behandelingen
complementary and alternative medications
complementary medicine
complete mesocolic excision
complete remission with vismodegib
COMPLETE study
complex karyotype
COMPOSE-studies
computationele pathologie
Computer-geassisteerde chirurgie
concomitant mutations
concomitant use
CONCORD-2
CONCORD-3
concurrent chemoradiotherapy
conditionele ziektevrije overleving
CONDOR trial
congenital heart disease
congestive heart failure
conjunctival melanoma
CONKO-004
connexine 30
consensus molecular subtypes
conservative management
CONSIGN
consolidation with WBRT or stem-cell transplantation
consoliderende radiotherapie
Consomic Xenograft Model
contemporary hormonal contraception
continuous tumor-size-based end points
CONTINUUM-studie
contralateraal mammacarcinoom
contralateral breast cancer
contralaterale borstkanker
contralaterale mastectomie
contralaterale profylactische mastectomie
CONVERT-studie
CONVINCE-studie
COPD
copy number alteration screening
copy number loss
corpus uteri cancer
corticosteroïden
corticosteroids
cost-effectiveness
cost-effectiveness of CAR T-cell therapy
cost-effectiveness of intraoperative MRI
cost-effectiveness of lung cancer screening
Costa RIca
Costa Rica HPV Vaccine Trial
cotinine
coxibs
CP-CML
CP-genen
CpG-B
CPI-613
CPIs
CPM
CPPT
CPX-351
CRA
craniotomie
CRBSI
CRC
CRC detection
CRC diagnosis
CRC incidence
CRC incidence in Canada
CRC intrinsic subtypes
CRC liver metastases
CRC risk
CRC risk in Lynch syndrome
CRC stage distribution
CRC survival
CRC survivors
CRC-biomarkers
CRC-diagnose
CRC-risico
CRC-screening
CRCD
CREATE-studie
crenigacestat
CRF
cribriform groeipatroon
CRICKET trial
crizotinb
crizotinib
crizotinib-resistant ALK-positive NSCLC
CRLM
CRLX101
CRN
CROSS
CRP
CRP-niveau
CRPC
CRPC with bone metastases
CRS
CRS HIPEC
CRS-207
CRS-HIPEC cost effectiveness
CRT
CRT versus CT
CSCC
CSCCs
CSM
CT
CT examinations
CT lung cancer screening
CT-based biomarkers
CT-longkankerscreening
CT-P10
CT-screening longkanker
cT1-2N0 breast cancer
cT1T2No OTSCC
CTCAE
CTCL
CTCs
ctDNA
CTLA-4
CTLA-4 blokkade
CTLC
CTP
CUDC-907
CUETO
CUP
curatie
current or former smoking
cutaan squameus celcarcinoom
cutaan squameus celcarcinoom van hoofd en hals
cutaan T-cel lymfoom
cutane bijwerkingen
cutaneous adverse events
cutaneous BCC
cutaneous HNSCC with regional lymph node metastasis
cutaneous malignant melanoma
cutaneous squamous cell carcinoma
CUX1-ALK rearrangement
CVD
CVSS-studie
CXB
CXM
cycline D1
cyclofosfamide
cyclophosphamide
cyclophosphamide-bortezomib-dexamethasone
CYP2D6 genotype
CYP3A
cyproteronacetaat
cyramza
cystectomie
cytarabine
CYTO-CHIP study
cytogenetisch normaal AML
cytokine-induced killer cell therapy
cytokines
cytology testing
cytoreductive surgery
D-2-hydroxyglutaraat
D-Rd versus Rd
D-VCd
DA-EPOCH-R versus R-CHOP
dabrafenib
dabrafenib plus trametinib
dabrefenib plus trametinib
dacomitinib
DADI
DAFI
daily aspirin
daratumumab
darm-microbioom
darm-stamcellen
darmflora
darmkanker
darolutamide
DART S1609 neuroendocrine cohort
DART-studie
dasatinib
dasatinib versus imatinib
DATA-studie
David A. Karnofsky Memorial Award and Lecture
davoli
DAWN-studie
DAWT
DBCG 07-READ studie
DBMS
DC-CIK
DCE-MRI
DCF chemotherapy
DCIS
DCIS and node-negative breast cancer
DCIS before age 50 years
DCIS grading
DCOG-LATER cohort
DCOG-LATER cohort study
DCOG-LATER studie
dd-chemotherapie
DDCT
DDR gene aberrations
de novo metastatic prostate cancer
de novo stage IV HER2-positive MBC
De-ESCALaTE HPV study
de-escalation of TKIs
Debio0932
Decipher
decision support system
decitabine
dedifferentiated chordoma
deep learning
defactinib
definitive radiotherapy
degarelix
DEL
delayed hearing loss
delirium
dementia
Denemarken
denosumab
dense breast tissue
dentaal trauma
depatux-M
depressie
depression
depth of response
dermatofibrosarcoma protuberans
desmoïd
desmoid tumors
DESMOPAZ study
DESTINY study
DESTINY-studie
detectie
Detectie borstkanker
detectie colorectaalkanker
detecting genomic biomarkers in plasma versus tissue
detection advanced neoplasia
detection bias
detection early-stage OPSCC
detection of CTCs during follow-up
detection of invasion of detrusor muscle
detection of microsatellite instability
detection of mutations in ctDNA
detection of non-index lesions
detection of prostate cancer
detection of relapse
determinants of breast cancer risk
determinants of optimal adjuvant therapy
determinants of tumor cell PD-L1 expression
dexamethason
dexanethasone
dexrazoxane
DFP-10917
DHA
DHAP
DHL
diabetes
diabetes and cancer risk
diabetes mellitus
diagnose longcarcinoom
diagnostic low-dose ionizing radiation in youth
DICER1 pathogenic variants
diet qualiity
diet quality
dietary carbohydrate quality and human health
dietary fiber
dietary fiber and yogurt
dietary intake
dietary supplement use
differences in treatment outcomes
different cancer types
differential ribosome measurements of codon reading
differentiated thyroid cancer
difficult patients
diffuse large B cell lymphoma
diffuse large B-cell lymphoma
diffuse large B-cell lymphoma-specific mortality
Diffuse optical spectroscopic imaging
diffuse type TGCT
diffuse-type giant cell tumor
diffusion-weighted MRI
diffuus grootcellig B-cel lymfoom
diffuus intrinsiek ponsglioom
digital breast tomosynthesis
digital breast tomosythesis
digital screening mammografie
DigniCap
digoxine
DII
DIPG
DIPG-BATS studie
direct-acting antivirals
discontinuation imatinib for CML in children
discontinuation of anti-PD-1 antibody therapy
discontinuation of immune suppression
disease trajectories and mortality after breast cancer
disease-free survival
diseases and deaths in middle-aged adults
disontinuation of trastuzumab
disparities by race ethnicity and age
distal cholangiocarcinoma
distal rectal cancer
distale pancreatectomie
distant disease-specific survival
distant metastatic breast cancer
distant recurrence of breast cancer
distress
Distress Thermometer
DLBCL
DMFS
dMMR CC
dMMR PDAC
DN
DNA damage immune response
DNA Damage Immune Response signatrue
DNA promoter-hypermethylering
DNA-methylering
DNA-test
DNMT3A-mutatie
docetaxel
documentaire
doelgerichte behandeling
donor clonal hematopoiesis
DoR
dormancy-genen
dosisescalatie
DOT1L
double expressor DLBCL
DOVIGIST-studie
doxorubicin delivery from ultrasound-triggered liposomes
doxorubicine
DPYD genotyping
DPYD*2A variant carrying cancer patients
droge mond
droplet digital PCR
drug response predictor
drug-drug interactions
drye eye syndrome
DSMM XI-studie
DSRCT
DSTP30865
dt-GCT
DTC
DTCs
ductaal carcinoom in situ
ductal carcinoma in situ
dunne-darmadenocarcinoom
dunne-darmneoplasie
DUO study
duration of adjuvant trastuzumab
duration of response
durvalumab
durvalumab plus olaparib plus cediranib
dutasteride
Dutch Bone Metastasis Study
duvelisib
DYNAMIC study
DYNAMO study
DYPD genotyping
dysfagie
dyslipidemia
dyspnoe
e-sigaretten
E1912 study
E2F8
E3805-studie
E3A06 study
E3N
E3N cohort
E4
E5103 study
E75
EA
EAC
early and locally advanced breast cancer
early AYAs
early breast cancer
early cancer surveillance
early diagnosis
early metabolic response
early mortality
early noninvasive detection of response
early onset CRC
early onset female cancer survivors
early palliative care use
early phase ICI-trials
early recurrence
early stage breast cancer
early stage ER-positive breast cancer
early thymic precursor acuut lymfoblastische leukemie
early thymic precursor-like phenotype ALL
early-life alcohol intake
early-onset colorectal cancer
early-onset familial breast cancer
early-onset severe infections
early-stage breast cancer
early-stage endometrial cancer
early-stage Hodgkin lymphoma
early-stage lung cancer
early-stage non-small cell lung cancer
early-stage pediatric HL
EBV
EC
ECD
Echelon-1 studie
ECHELON-1 study
ECHELON-2 study
ECHO-202 KEYNOTE-037
ECOG PS 2
ECOG-ACRIN 2511 study
ECOG-ACRIN 5508 study
ECOG-ACRIN E1912 study
ECOG-PS
economic evaluation
ECX)
Edinburgh Pain Assessment and management Tool
educational level
één-maands mortaliteit
eenarmige versus gerandomiseerde fase 2-studies
eerdere kanker
EF-14
efficacy of medications for reduction of risk of primary breast cancer in women
EFVPTC
EGFR
EGFR amplified glioblastoma
EGFR copy number gain
EGFR inhibition resistance
EGFR mutated advanced non-small cell lung cancer
EGFR mutated NSCLC
EGFR mutation-positive advanced NSCLC
EGFR mutation-positive NSCLC with leptomeningeal metastases
EGFR T790M
EGFR T790M-positive NSCLC in elderly patients
EGFR-blokkade
EGFR-mutant and MET-amplified NSCLC
EGFR-mutant lung adenocarcinoma
EGFR-mutant non-small cell lung cancer
EGFR-mutant NSCLC
EGFR-mutant NSCLC with liver metastases
EGFR-mutated advanced non-small cell lung cancer
EGFR-mutated advanced non-small-cell lung cancer
EGFR-mutated lung adenocarcinoma
EGFR-mutated non-small cell lung cancer
EGFR-mutated NSCLC
EGFR-mutatie
EGFR-mutaties
EGFR-TKI
EGFR-TKIs
EGFR+ and ALK+ NSCLC
EHCC
eierstokkanker
eiwitbiomarkers
ELCC 2017
elderly cancer patients
elderly patients
electric power morcellation
electronic nose
elevated vitamin B12 levels
ELIANA study QOL analysis
Eliasof
ELOQUENT-3 study
elotuzumab
ELRP
ELSA
eltrombopag
ELTS-score
emactuzumab
EMBRACA study
EMBRACA-studie
EMBRACE-studie
embryonale hersentumoren
EMD
EMERGING-CTONG 1103 study
emesis
EMILIA
emotionele uitputting
EMT
EMVI
encorafenib
encorafenib plus binimetinib
ENCORE-601 study
end-of-life care
end-of-life zorg
ENDEAVOR-studie
endocriene behandeling
endocriene effecten
endocriene therapie
endocrine deficiency
endocrine diseases
endocrine therapy
endocrine therapy adherence
endocrine therapy for breast cancer
endocrine therapy resistance
endocrine treatment
endocrine treatment versus chemotherapy
endometrial ancer
endometrial cancer
endometrial cancer risk
endometrial cancer surgery
endometrioïd endometriumcarcinoom
endometrioïd epitheliaal ovariumcarcinoom
endometrium-adenocarcinoom
endometriumcarcinoom
endometriumkanker
EndoPredict
endotheliaal ovariumcarcinoom
ENDS
energetic capacity
ENESTfreedom
enfortumab vedotin
ENGOT-OV16 NOVA study
ENGOT-OV16 NOVA trial
enhanced recovery after surgery
enhancer of zeste homolog 2
ENITEC consortium
ENKTL
ENLIVEN study
enocrafnib
ensartinib
entecavir
enterovirus
enthusiasm hypothesis
entrectinib
Environmental Quality Index
enzalutamide
enzalutamide for castration-resistant prostate cancer
ENZAMET study
enzastaurine
EOC
EOPM
EORTC
EORTC 10995
EORTC 1325 Keynote-054 studie
EORTC 18071
EORTC 22922 10925-studie
EORTC 22952-26001 trial exploratory analysis
EORTC 26101 analysis
EPA
epacadostat
EpCAM-positieve tumoren
ependymoom
EPHOS-B
epi-drugs
EPIC
EPIC cohort
EPIC-analyse
EPIC-NL
EPICAP-studie
epidural use
epidurale metastasen
epigenetic editing
epigenetische stabiliteit
epigenetische veranderingen
epilepsy risk factors
epirubicin
epitheliaal ovariumcarcinoom
epithelial ovarian cancer
epithelial ovarian cancer risk
epithelial ovarian cancer survivors
epithelial ovarian carcinoma
Epitopes-HPV02 ancillary study
Epitopes-HPV02 study
EPOC
Epstein-Barr virus-geïnduceerde lymfoproliferatieve ziekte
EQoL-MDS
ER positive breast cancer
ER status
ER- en PR-testen
ER-negatief mammacarcinoom
ER-negatieve borstkanker
ER-negatieve tumoren
ER-positief HER2-negatief gevorderd mammacarcinoom
ER-positief mammacarcinoom
ER-positieve borstkanker
ER-positive advanced breast cancer
ER-positive breast cancer
ER-positive HER2 negative breast cancer
ER-positive HER2-negative breast cancer
ER+ HER2-
ER+ HER2- BC
ERA 223 study
ERAS
ERBB2 HER2-positive metastatic breast cancer
ERBB2 mutations in solid tumors
ERBB2 plasma copy number
erdafitinib
Erdheim-Chester disease
erfelijke borst- en eierstokkanker
erfelijke syndromen
erfelijkheid
ERG- and PTEN-defined prostate cancer
eribulin
eribulin plus everolimus
eribuline
ErkentNIS
erlotinib
ersatzdroge
Erβ1
Erβ2
ES-NSCLC
ES-SCLC
ESCC
ESCC detection by microRNA profiling
ESD
ESGC
ESHAP
ESMO
esomeprazole
esophageal adenocarcinoma
esophageal and GEJ adenocarcinoma
esophageal cancer
esophageal squamous cell carcinom
esophageal squamous cell carcinoma
esophagogastric cancer surgery
ESPAC-4 secondary analysis
ESR1-amplificatie
estetrol
ESTHER cohort study
esthesioneuroblastoom
esthetische uitkomst
estrogen monotherapy
ET
etirinotecan pegol
etnische diversiteit
ETP-ALL LBL
ETS
EU-regelgeving
EURECCA
Euro-E.W.I.N.G.99
Euro-Ski
EURO-SKI studie
EUROCARE-5
European cancer mortality
European Code against Cancer
Europese kankermortaliteit
EURTAC
EUTOS
EV-201 study
EV-assay
evaluation of hematuria
EVAN study
everolimus
everolimus plus exemestane for postmenopausal HR+ HER2- advanced breast cancer
everolimus plus letrozole and metformin
everolimus plus pazopanib
everyday clinical practice
evofosfamide
Ewing and Ewing-like sarcoma in adults
Ewing sarcoma
Ewing sarcoom
Ewing-2008
ex vivo IFNγ production
exceptional responder
EXCITE-studie
exemestaan
exemestaan plus everolimus
exemstaan
exercise intervention in cancer patients
exercise versus usual care
exhaled breath tests
exome sequencing-based screening
exosomen
expansie van fase 1-studie PCD4989g
Exploratieve analyse MARQUEE-studie
exposoom
expressie stromagenen in CRC
EXPRESSION III-studie
extended follow-up of PALOMA-2 study
EXteNET
ExteNET-studie
extension of aromatase inhibitor therapy
extensive stage
extensive-stage small cell lung cancer
extensive-stage small-cell lung cancer
external beam radiation therapy
extracapsular extension in sentinel node
extracorporeal photopheresis
extrahepatisch cholangiocarcinoom
extranodal natural killer T-cell lymphoma
extranodale extensie
extrapleural pneumonectomy
extrauterine disease
EZH2
FACE
facial nerve function
facial-aging app
facility volume
facilty volume and mortality
factors predicting invasive breast cancer recurrence
FALCON
false positive FIT
familair mammacarcinoom
familiaal colorectaalcarcinoom
familiaal risico
familiaire adenomateuze polyposis
familiaire adenomateuze popyposis
familial platelet disorder
familiale adenomateuze polyposis
familiegeschiedenis
familiegeschiedenis prostaatkanker
family history
family history of breast cancer
family history of cancer
FaMRIsc study
fase 2-studie BOLERO-4
fase 2-studie BOLERO-6
fase 2-studie KEYNOTE-224
Fase 2-studie SWOG S0801
fase 3- studie DREAM
fase 3-studie AURA3
fase 3-studie BrighTNess
fase 3-studie COLUMBUS
Fase 3-studie CRITICS
fase 3-studie ETNA
fase 3-studie FATA-GIM3
fase 3-studie GEC-ESTRO
Fase 3-studie KEYNOTE-045
fase 3-studie METEOR
Fase 3-studie MONALEESA-3
fase 3-studie MONALEESA-7
fase 3-studie NETTER-1
Fase 3-studie PERSEPHONE
fase 3-studie PRODRIGE 9
Fase 3-studie SAKK 75 08
Fase 3-studie SWOG S9921
fase 3-studie TROG 05.01
fase 3-studies
fatal ICI-associated toxic effects
fatalisme
fatigue
fatigue in cancer patients
favorable histology Wilms tumor
FCR
FCT
FDA-approved novel oncology drugs
FDG-PET
FDG-PET CT
FDG-PET scanning
feasibility
febriele neutropenie
fecale immunochemische test
female breast cancer risk
fentanyl
fentanyl sublinguale spray
fenylketonurie hyperfenylalaninemie
fermented dairy foods
fertiliteitspreservatie
fertility drugs
fertility treatment
fertility-sparing surgery
FGFRs
FH02 study
FHWT
FIA
FIGHTDIGO-studie
fijne motoriek
fijnstof
FIL-HD0801 study
Finale analyse FIRST-studie
finale analyse van GOG 240-studie
finale overlevingsresultaten van KEYNOTE-006
financiële toxiciteit
finasteride
fine-needle biopsy
FinXX-studie
FIR-studie
FIRE-3
firefighters
FIRES
first line therapy
first relapse B-ALL in children and AYAs
first-degree relatives of pancreas cancer patients
first-line carboplatin versus cisplatin
first-line CLL treatment
first-line dose-dense early postoperative intraperitoneal chemotherapy
first-line mFOLFOX6 plus bevacizumab versus cetuximab
first-line osimertinib
first-line pembrolizumab
first-line pembrolizumab for advanced NSCLC with low PD-L1 expression
first-line radioembolization plus chemotherapy
first-line trastuzumab
first-line Tumor Treating Fields plus chemotherapy
first-relapse rhabdomyosarcoma
FIRSTANA-studie
fistula
FIT
FIT cohort
FIT screening
FIT-detection of advanced colorectal neoplasia
FIT-screening
fitheid
fitness
five miRNA-model
five-miRNA based classifier
five-year PROs
five-year survival outcomes
five-year survivors of adolescent and young adult cancer
fixed duration of venetoclax-rituximab
FKBPL
FL
FLAURA study
FLAURA-studie
flavonoïden
flexibele sigmoïdoscopie
flexibele-sigmoïdoscopie
FLOT4 study
FLOT4-studie
FLT3-internal tandem duplication mutated AML
FLT3-ITD positive AML
fluciclovine versus PSMA PET-CT
fludarabine
FLUOGLIO-studie
fluoropyrimidine therapy
fluoropyrimidines
fluoroscopie
fluorouracil-leucovorin
FLYER study
FNMTC
focal adhesion kinase
FOCUS-cohort
Fol-BRITe study
FOLFIRI
FOLFIRINOX
FOLFOX
FOLFOX4
FOLFOXIRI
FOLFOXIRI plus panitumumab
foliumzuur
FOLL05-studie
folliculair lymfoom
follicular lymphoma
follow-up after discontinuation
Follow-up analyse van CheckMate 067-studie
follow-up analyse van JFMC34-0601
follow-up van overlevers
formaldehyde
FOrMAT-studie
fosaprepitant
fosaprepitant meglumine
fotofarmacologie
FOXA1-expressie
FOXA2
FOXC1
FPD AML
fractionated gamma knife radiosurgery
fractionated stereotactic radiotherapy
fracturen
fractures
fractuurrisico
fragiele ouderen
fragiliteit
frequency and outcomes of brain metastases
frequent cystoscopy
FRESCO study
fresolimumab
front-line fludarabine-cyclophosphamide-rituximab
front-line ibrutinib for CLL patient populations not included in RESONATE-2
frontline targeted therapy plus low-intensity chemotherapy
frontline therapy for AML in elderly patients
fruit
fruit and vegetable consumption
fruquintinib
FSRT
FSS versus RS
FTD versus HD-MA
FTL3-mutatie
FUJI cohort
fulvestrant
fulvestrant plus palbociclib
fulvestrant versus AIs
FUS-ERG and RUNX1-CBFA2T3
fusion gene
Fusobacterium nucleatum
fysieke activiteit
G-CSF support
G-CSFs
G84E
gain-of-function mutatie
gait speed
galactography
galblaascarcinoom
GALEN study
galeterone
gallium-68 labelled PSMA-11 PET
GALLIUM-studie
galunisertib
galwegcarcinoom
gamma knife radiosurgery
ganglioside-monosialic acid
ganitumab
GARD
garlic
gastric adenocarcinoma
gastric cancer
gastric or gastro-esophageal junction cancer
gastric or gastroesophageal junction adenocarcinoma
gastric or gastroesophageal junction cancer
gastric or GEJ adenocarcinoma
gastritis
gastro-intestinale mucositis
gastro-intestinale stromale tumoren
gastro-oesofagaal adenomcarcinoom
gastroenteropancreatic neuroendocrine tumors
gastroesophageal adenocarcinoma
gastrointestinal stromal tumor
gastrointestinal stromal tumors
gastroïntestinale kanker
gastroïntestinale stromale tumoren
Gattelli
GAUDI
GBC
GBCA
GBM
GBM in elderly patients
GBS
GBSM
GBV-C
GC
GC1008
GC4419
GCA
GCC
GCT
GCTB
GCTs
GD
GDP
GEC
GeDDiS-studie
gedifferentieerd schildkliercarcinoom
gedissemineerde tumorcellen
gefitinib
gefitinib alone or with chemotherapy
gefitinib continuation after progression
GEICAM 2003-11_CIBOMA 2004-01 study
GEICAM 2010-04 study
gelokaliseerd prostaatcarcinoom
GEM
gemcitabine
gemcitabine plus cisplatin induction chemotherapy
gemcitabine-eribulin combination
gemcitabine-trastuzumab-pertuzumab after pertuzumab-based therapy
gemcitabineresistentie
gemetastaseerd mammacarcinoom
gemetastaseerd melanoom
gemetastaseerde borstkanker
gemetastaseerde borstkanker; trastuzumab
gemetastaseerde colorectaalkanker
gemtuzumab ozogamicin
gemtuzumab ozogamicine
gender differences
gene expression profiles
geneesmiddelinteracties
Generations Study
genetic prognostic and predictive factors
genetic testing
genexpressie
genito-urinaire maligniteiten
genmethylering
genome sequencing
genome-wide association study
genome-wide diet-gene interaction
genomic biomarkers predicting anti-PD-(L)1 response
genomic correlates
genomic correlates of progression or response
genomic determinants of clinical outcomes
genomic profiling
genotyping lung adenocarcinoma
genvarianten
GEP-NETs
GeparNuevo study
GeparQuattro-studie
GeparSepto
GeparSepto long-term outcomes
GeparSixto trial
gepegyleerd liposomaal doxorubicine
gerandomiseerde fase 2-studie PrE0102
GERD treatment
Gerecke
geriatirc patients
Geriatric Prognostic Indicator
germ cell tumors
germline BARD1 gene variants
germline BRCA pathogenic variant
germline BRCA-mutated metastatic pancreatic cancer
germline BRCA2 mutations
germline mutaties
germline mutations
germline variants in natural killer cells
geserreerde poliepen
geslachtshormonen
gestation and birthweight of offspring
gestationele trofoblasttumor
GETNE-TRASGU study
GETUG-AFU 16 study 112-months follow-up
gevorderd cervixcarcinoom
gevorderd maag-adenocarcinoom
gevorderd melanoom
gevorderd niercelcarcinoom
gevorderde borstkanker
gevorderde maagkanker
geweichtsverlies
gezondheidsutiliteitsindex
gFOBT
GFR
GFR; niercelcarcinoom; urotheelcarcinoom
GHSG HD13-15 trials
GI adverse events
giant-cell tumor of bone
gilteritinib
GIST
GK-SRS with or without EGFR-TKIs
GLARIUS-studie
glasdegib
Gleason score 9-10 prostate cancer
glembatumumab vedotin
glioblastoma
glioblastoma multiforme
glioblastoma recurrence
glioblastoma with methylated MGMT promoter
glioblastoom
glioma
glioma risk
gliomas
gliomen
glioom
glitazonen
Global Burden of Cancer
Global Burden of Disease Study
glottic squamous cell carcinoma
glucocorticoid treatment
glucose lowering drugs
GLUT-
GLUT-14
glutathion-S-transferase P1
glycaan-gerelateerde genen
glypicaan-1
GM-CSF
GNCC
GnHRa
GnRH-agonist
GO
GOG-0213 studie
GOG-0213 study
GOG-0218 final OS-analysis
GOG-0218 studie
GOG-0277
Golestan Cohort Study
gonadotropine
Google Translate
GORTEC 2007-01 studie
gosereline
GOYA-studie
graft failure
graft versus host disease
graft-versus-host disease
graft-versus-host disease prophylaxis
GRASPA
GRECCAR 2-studie
GREEN study subgroup analysis
grijpkrachtverlies
grip strength
groeicurves naevi
groeisnelheid
groenten
groentenconsumptie
grootcellig granulair lymfocytaire leukemie
grootcellig neuro-endocrien longcarcinoom
grootte van lymfekliermetastasen
grote-korrel lymfocyten leukemie
growth hormone deficiency
growth rate of untreated hemangioblastomas
GSK2857916
GU-toxiciteit
guadecitabine
guanylaatcyclase
GVAX pancreas
GVHD
GVHD prevention after haploidentical HCT
GWAS
gynecological brain metastases
gynecologische maligniteiten
H. pylori
haarverlies
hafnium oxide nanoparticle
HAI
HAIC
hairy cell leukemia
hairy-cell leukemie
hallmarks of cancer
HALO 202-studie
Ham-Wasserman lecture
Hamilton Fairley Award
hand-voet huidreacties
hand-voet syndroom
hand-voetsyndroom
HannaH study final analysis
haplo-HSCT
haplo-HSCT versus chemotherapy
haplo-identieke HSCT
haplo-SCT
haploidentical versus unrelated SCT
haploidentical; sibling; matched unrelated donor
HART
hartfalen
hartfalen na auto-HCT
HBOC
HBV-related HCC
HBV-related HCC risk
HBV-vaccinatie
HC
hcc
HCC overall survival
HCC with portal vein tumor thrombus
HCT
HCV
HD IL-2
HD12 study
HD16 trial
HD18-studie
HD9 study
HDAC inhibition
HDR-brachytherapie
head and neck cancer
head and neck cancer risk after hematologic cancer
head and neck procedures
head and neck squamous cell carcinoma
head en neck cancer
health maintenance practices
Health Professionals Follow-up Study
health promotion among cancer survivors
health-related quality of life
healthy immigrant effect
healthy older adults
heavily pretreated HR-positive HER2-negative metastatic breast cancer
heavy smokers
hedgehog-signaalroute
heldercellig niercelcarcinoom
heldercellig ovariumcarcinoom
Helicobacter pylori
HELIOS study
hematologic malignancies in older patients
hematologic malignant neoplasms
hematologische maligniteiten
hematopoietic cell transplantation
hematopoietic score predicts outcomes
hematopoietic stem cell transplantation
hematopoietic stem cell transplation
hematopoïetische celtransplantatie
hemispheric-specific clinical presentation
hepatectomy in academic versus community cancer center
hepatitis B virus infection
hepatitis B-virus
hepatitis C
hepatocallular carcinoma
hepatocellulair carcinoom
hepatocellular carcinoma
hepatocellular carcinoma with portal vein invasion
hepatospleen T-cel lymfoom
hepatotoxiciteit
hepatotoxicity
HER2
HER2 amplification
HER2 exon 20 insertions
HER2 pro-oncogene signalering
HER2-amplified mCRC
HER2-expressie
HER2-expressing cancers
HER2-gedreven NSCLC
HER2-mutant lung cancer
HER2-negatief mammacarcinoom
HER2-negatieve borstkanker
HER2-negatieve MBC
HER2-negative
HER2-negative breast cancer
HER2-negative metastatic breast cancer
HER2-overexpressing breast cancer
HER2-positief mammacarcinoom
HER2-positief metastatisch mammacarcinoom
HER2-positieve borstkanker
HER2-positieve vroege borstkanker
HER2-positive ABC MBC
HER2-positive advanced breast cancer
HER2-positive breast cancer
HER2-positive breast cancer neoadjuvant lapatinib plus trastuzumab
HER2-positive breast cancer with brain metastases
HER2-positive EAC
HER2-positive early breast cancer
HER2-positive localized breast cancer
HER2-positive MBC
HER2-positive metastatic breast cancer
HER2-positive salivary duct carcinoma
HER2-scoringsysteem
HER2-screening
HER2-targeted CAR T cell therapy
HER2-targeted therapies
HER2-targeted therapy
HER2+ BC
HER2+ breast cancer
HER3-mutant mammacarcinoom
HERA
HERBY-studie
herceptin
herceptin-biosimilar
herceptine
Heritage
heropname
herpes zoster after autologous stem cell tranplantation
hersenmetastasen
hersenmetastasen mammacarcinoom
hersenmetastasering
hersenmicrobloedingen
hersentumoren
Heterocephalus glaber
heterogeneity between SEER counties
HF-WBI
HFSRT
HGG
HGS OC
HGSOC
HIFU
high risk locally advanced rectal cancer
high risk melanoma
high RS
high sensitivity C reactive protein
high-dose intensity-modulated chemoradiotherapy
high-dose-rate brachytherapy
high-grade glioma
high-grade prostate cancer
high-intensity focused ultrasound
high-intermediate and high risk early stage EC
high-mobility group box 1
High-molecular-mass hyaluronan
high-risk ALL in children
high-risk breast cancer
high-risk cancer surgery
high-risk endometrial cancer
high-risk extremity trunk STS
high-risk features
high-risk luminal breast cancer
high-risk lymphoma
high-risk melanoma
high-risk neuroblastoma
high-risk prostate cancer
high-risk rhabdomyosarcoma
high-risk smoldering multiple myeloma
high-risk uveal melanoma
HIIT
HiLo trial
HIPEC
HIPEC + CS
histological biomarkers
histologische regressie
histopathologic features
HIV
HIV AIDS
HIV infection
HIV infection in elderly patients
HIV RNA
HIV-associated Kaposi sarcoma
HIV-infection
HL
HL diagnosis during pregnancy
HL-behandeling
HLA antigen mismatch
HLA-matched or alternative donors
hMPV
HMR 2.0
HNC
HNCs
HNSCC
HNSCC surgery
Hodgkin lymfoom
Hodgkin lymphoma
Hodgkin lymphoma in children and adolescents
Hodgkin's lymfoom
Hodgkin’s lymphoma
hofd-hals Merkel celcarcinoom
hoge dosering chemotherapie
Hokusai VTE-Cancer studie
homeobox B13
homocysteïne
homologous recombination deficiency
hoofd hals squameus celcarcinoom
hoofd halscarcinoom
hoofd halskanker
hoofd-hals melanoom
hoofd-hals squameus celcarcinoom
hoofd-halscarcinoom
hoofd-halskanker
hoofdhuidkoeling
hoog-risico B-ALL
hoog-risico cervixcarcinoom
hoog-risico CML
hoog-risico melanoom
hooggradig sereus ovariumcarcinoom
horizontale transfer
hormonal therapy
hormonal therapy resistance
hormoonreceptor positieve borstkanker
hormoontherapie
hospital volume
hospitalisatie
hospitalization
hot flashes
HOVON 105 ALLG NHL 24
How Long studie
HP SCC
HPC-SFT
HPD
HPTC
HPV
HPV ctDNA
HPV DNA in penile cancer and intraepithelial neoplasia
HPV DNA persistence
HPV status
HPV types 16 18 in cervical precancers
HPV vaccination
HPV-16 18 vaccin
HPV-associated epithelial cancers
HPV-associated oropharyngeal squamous cell carcinoma
HPV-FOCAL trial
HPV-infectie
HPV-negative HNSCC
HPV-orofarynxcarcinoom
HPV-positive oropharyngeal cancer
HPV-positive oropharyngeal squamous cell cancer
HPV-typen
HPV-vaccinatie
HPV+OPSCC
HPV16-related cancerISA101
HR-deficiëntie
HR-NB
HR-NL81 SIOPEN
HR-positief mammacarcinoom
HR-positief metastatisch mammacarcinoom
HR-positive advanced postmenopausal breast cancer
HR-positive breast cancer
HR-positive breast cancer brain metastases
HR-positive early-stage breast cancer
HR-positive HER2-negative advanced breast cancer
HR-positive HER2-negative metastatic breast cancer in older women
HR-positive metastatic breast cancer
HR-status
HR+ HER2- MBC
HR+ HER2- vroeg-stadium mammacarcinoom
HR+ HER2+ breast cancer
HR+ MBC
HRBOC
HRQoL
HRQOL in prostate cancer
HRT
HRT versus CRT
HSC
HSCT
HSCT-bijwerkingen
Hsp70
HT
hTERT-DCs
hu3F8
huidkanker
huidkankerscreening
huidmaligniteit
huidneoplasmen
huisartsenzorg
humaan papillomavirus
human equilibrative nucleoside transporter 1
human readers versus machine-learning algorithms
hybrid minimally invasive esophagectomy
hyperbaric oxygen therapy
hypercalcaemia of malignancy
hypercalcemie
hyperemesis gravidarum
hyperprogressive disease
hyperproliferatie van stamcellen
hypertensie
hypertension
hyperthermic intraperitoneal chemotherapy plus cytoreductive surgery
hyperthermische intraperitoneale chemoperfusie
hypervascular intracranial tumors
hypodiploid ALL in children
hypofarynxcarcinoom
hypofractionated IMRT
hypofractionated postmastectomy radiotherapy
hypofractionated stereotactic radiotherapy
hypofractionated versus conventional RT
hypofractionated versus conventionally fractionated whole-breast irradiation
hyponatremie
HYPOR
HYPRO
i-ALCL
iAMP21
IARC
IBC
IBCSG 23-01 trial
IBD
IBIS II
IBIS-I
IBM Watson
IBR
ibrutinib
ibrutinib discontinuation
ibrutinib for CLL
ibrutinib plus fludarabine
ibrutinib plus palbociclib
ibrutinib plus venetoclax
ibrutinib versus ofatumamab
ibuprofen
ICARIA-MM study
ICB
ICBP SURVMARK-2 study
ICC
ICI therapy in IBD patients
ICI treatment
ICI-related myocarditis
ICIs
ICIs for NSCLC
ICIs plus chemotherapy
ICLL07 FILO study
ICON6-studie
ICON8 study
ICON8-studie
ICPi
ICU-opname
idarubicine plus cytarabine plus nivolumab
iddEPC-studie
IDEA-collaboration
idelalisib
IDH mutation
IDH1-expressie
idiopathische membraneuze nefropathie
idiopatische MCD
Idylla
IELSG-19 studie
IELSG32-studie
IES
IFD
IFG
IFM 2009
IFN-onderhoudsbehandeling
IFRT
IGBT
IGF-1
IGF-1R expressie
IGF2-AS
IgM MGUS
IGT
IHCA
IHCC
IHGV mutational status
IIIA-N2 NSCLC
ijzersuppletie
IKFZ1-deletie
IKFZ1-deletion
IKZF1-deletie
IL-6
IL-8
ILC
illness perception and outcomes in cancer
iLLUMINATE study
image-guided intensity modulated radiation therapy
Imaging
imaging surveillance
IMAJEM-studie
imatinib
iMATRIX study
IMbrave 150 study
imetelstat
IMiDs
imiquimod
immediate vs deferred cytoreductive nephrectomy
IMmotion 151-studie
IMmotion151 trial
immune checkpoint blockade
immune checkpoint inbition for cancer
immune checkpoint inhibition
Immune Checkpoint Inhibitor
immune checkpoint inhibitor for NSCLC
immune checkpoint inhibitor-mediated diarrhea and colitis
immune checkpoint inhibitors
immune infiltration
immune markers of nivolumab response
immune-mediated diarrhea and colitis
immune-related adverse events
immunocheckpoint blockade
immunochemottherapy
immunocompromised cancer patients
immunoglobuline lichte-keten amyloïdose
immunophenotyping of TILs and PBLs
immunosuppressive therapy for management of MDS
immunotherapy
immunotherapy for advanced non-small cell lung cancer
immunotherapy for advanced stage cancer
immunotherapy-related pruritus
immutherapy
immuuncheckpointremmers
immuunrespons
immuunsuppressie
immuuntherapie
IMPAC
IMPACT
impact of adjuvant regimes
impact of age
impact of age at diagnosis on survival
impact of alcohol and smoking and FRP
impact of antibiotics
impact of attending surgeon
impact of biopsy frequncy on metastasis and mortality
impact of bone metastases
impact of centralization within hospital systems
impact of conditioning intensity
impact of cumulative exposure to premenopausal obesity
impact of detailed family history
impact of diet
impact of disease stage
impact of EGFR mutation and ALK rearrangement
impact of epigenetics on association of aspirin use with mortality after breast cancer
impact of ER status on survival
impact of facility caseload
impact of follow-up time
impact of germline BRCA1 or BRCA2 or PALB2 mutation on platinum response
impact of HIV infection
impact of hormone receptor status
impact of moderate-to-vigorous intensity physical activity
impact of molecular subtypes on incidence and prognosis of CNS metastases
impact of overweignt and obesity
impact of pre-existing CVD on mortality
impact of pregnancy on genomic landscape
impact of primary tumor surgery
impact of prior or concurrent antibiotic therapy
impact of prior therapy
impact on breast cancer incidence and mortality
impact on functional age and mortality
impact on outcomes
impact on sexual function
impact on survival
IMPACT-studie
IMPACT2
IMpassion130 study
IMpassion130 study updated results
IMpassion130 trial
IMPATTO study
IMPORT LOW study
IMpower130 trial
IMpower133 Study
IMpower150 study
IMpower150-studie
IMPRESS-studie
IMPROVE study
IMPT
IMRT
IMT
IMvigor211-studie
in situ mammacarcinoom
in utero chemotherapy exposure
incidence
incidence and mortality in England
incidence and outcomes
incidence of pneumonitis
incidence of T790M mutation in cfDNA
incidence trends
incident cancer risk
incident cardiovascular events
incidental pulmonary embolism in cancer patients
incidentally found pediatric brain tumors
incidentie
incidentie mammacarcinoom USA
increased α-fetoprotein
increasing dose intensity of chemotherapy
INDAR
independence
indeterminate pulmonary nodules
individual oncogenic HPV types
individual patient-level analysis
individualised axitinib regimen
indolent lymfoom
indolent mammacarcinoom
indoor tanning
inductie-chemoradiatie
inductiechemotherapie
induction chemotherapy
infants
infectie
infigratinib
inflammatie
inflammation cascade
Inflammatoir mammacarcinoom
inflammatoire voeding
inflammatory bowel disease
Inflammatory breast cancer
inflammatory markers
influenza vaccination
influenza vaccine effectiveness among cancer patients
influenzavaccinatie
infradiaphragmatic disease
inhaled corticosteroids
INHANCE-consortium
iNHL
iniparib
INITIATE study
iNNOVATE
iNNOVATE-studie
InnovaTV 201 study
INO-VATE studie
inotuzumab ozogamicin
inpatient versus outpatient administration
INSIGHT-studie
inspanning
Institute of Cancer Research
insulin resistance
insulin-like growth factor
insulinemie
insulineresistentie
intake of whole grains and dietary fiber
INTEGRATE
INTELLANCE 2 study
intellectual outcomes
INTENS-studie
intense androgen deprivation before prostatectomy
intensieve chemotherapie
inter- and intra-laboratory variation
Intergroup Exemestane Study
interim OS analysis of MONARCH 2
interim PET
intermediate recurrence score
intermediate- or high-risk GIST
intermediate-risk AML
intermittent nivolumab
intermittent versus continous PEG-asparaginase
intermitterende claudicatie
International Breast Cancer Intervention Study I
International Childhood Cancer Cohort Consortium
International Male BC Program
international variation in radiation dose
internet-steunprogramma's
interval breast cancer
interval cancers
interval-compressed VDC IE-chemotherapy
intervalcarcinomen
intervals to diagnosis
intra-tumor heterogeniteit
intracraniaal ependymoom
intraductale papillaire mucineuze neoplasie
intraductale papillaire mucineuze neoplasmen
intrahepatic cholangiocarcinoma
intrahepatisch cholangiocarcinoom
intraoperative peritoneal lavage
intraperitoneale chemotherapie
intratumoral F. nucleatum
intratumorale genetische heterogeniteit
intratumorale genoomdiversiteit
intrauterine devices
intravitale microscopie
intrinsic subtype analysis of BOLERO-2
intrinsiek subtype
intrinsieke subtypes
intrinsieke subtypes mammacarcinoom
invasieve borstkanker
invasive melanoma
invloed behandelcentrum op overleving
ioniserende straling
iontoforese
IORT
IOTA5 study
ipatasertib
IPH4102
ipilimumab
ipilimumab plus nivolumab
ipilimumab versus pembrolizumab
IPMN
ipsilateral breast event
IPTT
irAEs
IRd
IRE
irinotecan
irinotecan dose
IRIS
isatuximab
iscocitraatdehydrogenase
isocitraatdehydrogenaseremmer
isocitrate dehydrogenase wild-type glioblastoma in young adults
isolated breast pain
Italiaanse cultuur
ITOMIC-001 studie
IV versus IP chemotherapy plus bevacizumab
IVF
IVY study
IWDD
ixazomib
ixazomib maintenance
ixazomib of placebo toegevoegd aan lenalidomide-dexamethason
J-ALEX studie
JACC-studie
JACCRO GC-07 study
JACOB study
JAKARTA-2 studie
jandus
Janus Cohort
JAVELIN Lung 200 study
JAVELIN Merkel 200-studie deel B
JAVELIN ovarian cancer cohort
JAVELIN Renal 100-studie
JAVELIN Renal 101 study
JAVELIN Solid Tumor studie
JAVELIN Solid Tumor trial
JAVELIN Solid Tumor trial mesothelioma cohort
JCOG0203 trial
JCOG0504-studie
JCOG0910-studie
JCOG0912 study
JCOG1001-studie
JFMC37-0801 study
JGO
job-exposure matrices
jodium-131
joint replacement. B-cell neoplasms
JPHC nested case-control study
JULIET-studie
kanker
kanker bij kinderen
kanker-immunotherapie
kankerchirurgie
kankerincidentie
kankermortaliteit
kankermortaliteit 2015
kankerpijn
kankerrisico
kankerrrisico
kankersterfte
kankersubtypes
KATHERINE study
katheter
KC
KDD
keratinocytcarcinoom
keratinocyte carcinoma
Keratinocyte Carcinoma Chemoprevention Trial
kerncentrales
ketotifen
KEYNOTE-001
KEYNOTE-001 (secundaire analyse)
KEYNOTE-001 study
KEYNOTE-006 study
KEYNOTE-010
KEYNOTE-012
KEYNOTE-013 and -170
KEYNOTE-017 study
KEYNOTE-020
KEYNOTE-021
KEYNOTE-021 study
KEYNOTE-024
KEYNOTE-028
KEYNOTE-028 and -158 pooled analysis
KEYNOTE-028 studie
KEYNOTE-028 study
KEYNOTE-029
KEYNOTE-029 studie
KEYNOTE-040 study
KEYNOTE-042 study
KEYNOTE-045
KEYNOTE-048 study
KEYNOTE-052 studie
KEYNOTE-055
KEYNOTE-059 studie
KEYNOTE-061 studie
KEYNOTE-086 cohort A
KEYNOTE-086 cohort B
KEYNOTE-087
KEYNOTE-100 study
KEYNOTE-158 study
KEYNOTE-164
KEYNOTE-164 studie cohort B
KEYNOTE-180 study
KEYNOTE-181
KEYNOTE-181 study
KEYNOTE-189 studie
KEYNOTE-199 study
KEYNOTE-240 study
KEYNOTE-407
KEYNOTE-407 study
KEYNOTE-426 study
KEYNOTE-427 study cohort B
Khorana-score
Ki-67
Ki67
kidney cancer
kidney stones and risk of RCC and UTUC
kidney transplant recipients
kiemceltumor
kiemceltumoren
kinaseremmers
kinderkanker
KIT
klachten aromataseremmers
KLASS-01 studie
klassiek Hodgkin lymfoom
klein lymfocytair lymfoom
kleincellig longcarcinoom
kleincellig prostaatcarcinoom
kleincellige longkanker
kliernegatief mammacarcinoom
klierpositief mammacarcinoom
koffie
koffieconsumptie
kosten behandeling HER2-positief MBC
kosten van gezondheidszorg
kosteneffectiviteit hematologische middelen
kosteneffectiviteit screening
KP-BSI
KRAS
KRAS mutation
KRAS-mutatie
KRAS-mutaties
KRISTINE study
KRISTINE-studie
KS
KSHV-transmissie
kwaliteit van leven
L-COSY
LA-ESCC
LA-HNSCC
LA-NSCLC
laag-moleculairgewicht heparine
laag-vet voeding
laaggradig glioom
laaggradig niet-spierinvasief urotheelcarcinoom
laaggradig sereus ovarium- of peritoneaal carcinoom
laat recidief coloncarcinoom
LABC
LACE-Bio studies
LACE-Bio-II study
LACE-studie
LAcSCC
LADG
LADG versus ODG
LAFA-studie
LAHNC
LAM
LAM-SA 2007 study
LAMIS
Lancet Haematology
Lange-termijn analyse van SBG 2004-1 studie
lange-termijn follow-up van KEYNOTE-001
lange-termijn uitkomsten GeparQuinto
langerhanscel histiocytose
LAP07
laparoscopic versus open distal gastrectomy
laparoscopic versus open surgery
laparoscopie
laparoscopische chirurgie
laparoscopische hysterectomie
laparoscopische ingreep
laparoscopische resectie
lapatinib
LAPC
LAPC-1 trial
LARC
large brain metastases
laryngectomy
laryngectomy outcomes
larynxcarcinoom
larynxkanker
larynxpreservatie
Lasker Award
late bone marrow relapse of B-cell ALL in children
late lower cranial neuropathy
late mortaliteit
late recurrence
late recurrence after liver resection
late-onset anorectal disease
Lateral Node Study
LATITUDE study
LATITUDE-studie
LAVC
lazertinib
LCH
LCL161
LCNEC
LCS-6 KRAS
LDH response as prognostic biomarker
LE
LEA-studie
LEBS
leefstijl
leefstijl-geassocieerde maligniteit
leefstijlfactoren
leefstijlinterventies
leeftijd
left lung cancer
left ventricular global longitudinal strain
leighl
leiomyomatose
leiomyosarcoom
leisure-time physical activity
lenalidomide
lenalidomide maintenance
lenalidomide maintenance versus observation
lenalidomide plus rituximab
lenvatinib
lenvatinib plus pembrolizumab
leptomeningeal disease
leptomeningeal disease in metastatic melanoma patients
leptomeningeal disease recurrence
leptomeningeal metastases from NSCLC
leptomeningeale ziekte
letrozol
letrozole
letrozole for early breast cancer
leucine-rich repeating G-protein-coupled receptor 5
leukemia
leukemia cutis
leukemie
leukemie in kinderen
leukocyt-telomeerlengte
leukocytenattractie
leukocytosis
leumie
levensverwachting
levercarcinoom
levercelcarcinoom
levercelkanker
leverfunctie
leverkanker
levermetastasen
levofloxacin prophylaxis of infection
Leydig cell function
LFS
LGG
LGG before one year of age
LGSC
Li-Fraumeni syndrome
Li-Fraumeni syndroom
lichaamsgewicht
lichaamslengte
lichaamsomvang
lichaamsvet
lichaamsvetgehalte
lichte keten-geassocieerd Fanconi syndroom
lidocaïne
lieu
lifestyle
lifestyle intervention
ligating veins first versus arteries first
LINC00472
linsitinib
lip-SCC
LIPI
lipophilic statin use
liposarcoom
lipoxygenases
liquid biopsy
liquide biopten
Listeria expressing mesothelin
LITT
liver cancer
liver cancer mortality
Liver Cancer Pooling Project
liver cancer risk
liver metastatic breast cancer
liver-directed local therapy
LLPCa
LM
LMB-2
LMR
LNC-PATH score
lncRNAs
lobectomie
lobulair carcinoom in situ
lobulair mammacarcinoom
local consolidative therapy
local control
local recurrence
local therapy
localized pancreatic cancer
localized prostate cancer
localized renal cell carcinoma
localized versus advanced stage
localizing recurrent prostate cancer
locally advanced BCC
locally advanced cervical cancer
locally advanced gastric cancer
locally advanced head and neck squamous cell carcinoma
locally advanced intrahepatic cholangiocarcinoma
locally advanced laryngeal cancer
locally advanced lung cancer
locally advanced non-small cell lung cancer
locally advanced NSCLC
locally advanced pancreatic cancer
locally advanced pancreatic cander
locally advanced prostate cancer
locally recurrent brain metastases
locally recurrent or metastatic HER2-positive breast cancer
locatie
locatie van overlijden
locoregionaal recidief
locoregional recurrence
locoregional recurrence of breast cancer
Locoregional recurrent rhabdomyosarcome
locoregionale behandeling
LOH
lokaaal-gevorderd rectumcarcinoom
lokaal gevorderd prostaatcarcinoom
lokaal gevorderd rectumcarcinoom
lokaal recidiverend mammacarcinoom
lokaal-gevorderd hoofd-halscarcinoom
lokaal-gevorderd metastatisch mammacarcinoom
lokaal-gevorderd rectumcarcinoom
lomustine
lomustine plus temozolomide
loncastuximab tesirine
long-term cancer risk
long-term CRC risk
long-term disease-free breast cancer survivors
long-term follow-up
long-term follow-up BIG 1-98 trial
long-term follow-up KEYNOTE-012
long-term health outcomes
long-term outcomes
long-term responders
long-term results OlympiAD study
long-term risk of endocrine and metabolic diseases
long-term risk of hospitalization
long-term risk of infections
long-term somatic disease risk
long-term survival
long-term survivors NHL
long-term survivors of IDH-wildtype glioblastoma
long-term survivos of childhood cancer
long-term thyroid cancer risk
longadenocarcinoom
longcarcinoom
longer intervals after negative low-dose CT result
longfunctie
longkanker
longkanker-screening
longkankerchirurgie
longkankerscreening
longmetastasen
LORELEI study
lorlatinib
loss of heterozygosity 1p and 16q
loss of life expectancy
LOTUS-studie
low cT3 4 rectal cancer
low dose radioiodine ablation
low grade and anaplastic glioma
low grade glioma
low-dose aspirin
low-grade glioma in children
low-intensity chemotherapy
low-risk prostate cancer
lower extremity lymphedema
LP
LPHL
LPPG
LPS
LR-HL
LRBC
LRC
LRR
LS
LS-SCLC
LTL
LTLD
LUAD
LUME-Meso studie
luminal B
LUNA-studie
lung adenocarcinoma
lung adenocarcinoma brain metastases
lung and colorectal cancer
lung cancer
lung cancer mortality
lung cancer risk
lung cancer screening
lung cancer screening efficacy
lung cancer surgery
lung cancer survivors
lung nodule progression to cancer
LUNGSTAR
LuPSMA
LuPSMA-studie
lurbinectedin
lutathera
LUX-Lung3; LUX-Lung6
LV-V5
LY3039478
lycopeen
LYM-3002
LYM-3002 study
lymfadenectomie
lymfekliermetastasen
lymfeklierpositiviteit
lymfoblastisch non-Hodgkin lymfoom
lymfocyten
lymfocyteninfiltratie
lymfoedeem
lymfoïde neoplasie
lymfoom
lymph node burden
lymph node macrometastases
lymph node ratio
lymphadenectomy
lymphatic versus hematogneous dissemination
lymphedema
lymphoma
Lymphome Malin de Burkitt chemotherapy
lymphopenia
lymphoscintigraphy
Lynch syndrome
Lynch syndrome associated cancers
lynch syndroom
Lynch syndrooom
LYRA study
M-trap
MA.17R
MA.17R-studie
MA.27
maag maag-slokdarmovergangkanker
maag-slokdarmadenocarcinoom
maagadenocarcinoom
maagcarcinoom
maagkanker
MaBC
MabEase-studie
MABLE-studie
MACBETH-studie
MACRO2 TTD study
Magee Equation 3
MAGIC-studie
magnesiuminname
MAIA study
main-duct intraductal papillary mucinous neoplasms
maintenance therapy
maintenance treatment
maitenance chemotherapy
MAJA study
MAJA-studie
major head and neck surgery
MALDI-MS
male breast cancer
male pattern baldness
male sex disease-specific mortality
male-pattern baldness
malignant melanoma
malignant mesothelioma
malignant pleural disease
malignant pleural effusion
malignant pleural mesothelioma
maligne ascites
maligne glioom
maligne pleura mesothelioom
maligne pleuraal mesothelioom
Malmö Breast Tomosynthesis Screening Trial
Malmö Diet and Cancer Study
MALT lymfoom
MALT-IPI
MALT-lymfoom
mamacarcinoom
mammacarcinoom
mammacarcinoom in mannen
mammacarcinoom mannen
mammacarcinoom; SABCS 2015
mammacarcinoom. lichaamsgewicht
mammacarcinoomscreening
mammacarcinooom
mammacarcionoom
mammacarcioon
MammaPrint
MammaPrint-assay
mammografie
mammografiescreening
mammographic surveillance in young women
mammography
mammography breast cancer screening in high-risk males
mammography screening
MAN
management and outcomes
mannen
Mannuci
mantelcellymfoom
mantle cell lymphoma
MAPS IFCT-GFPC-0701 study
MAPS2-studie
MARCH
marginaal zone lymfoom
marginal zone lymphoma
MARIANNE study final results
MARIE study
MARIE-cohort
marihuana
marijuana use
marital status
marizomib
marker borstkanker
MARQUEE study
MARS mutation-adjusted risk score
masitinib
MasSpec Pen
mastectomie
mastectomy versus lumpectomy plus RT
maternal breast cancer risk
MATISSE-studie
matrix metalloproteïnase-8
MAVORIC study
MAVORIC-studie
MaxRP
MaxRT
MBC
MBI
MBL
MBMs
MCC
MCL
MCL in older patients
mCRC
mCRC extremes of survivorship
mCRPC
mCSPC
MD
MDS
MDS or AML
MDTB
meat consumption
meat intake
mebendazol
medical decision-making capacity
medische marihuana
mediterrane voeding
medium-sized brain metastases
MEDOCC
medullair schildkliercarcinoom
medullair thyroïdcarcinoom
medulloblastoma
medulloblastoma subgroups
medulloblastoom
meeroken
MEI
MEK- plus AKT-remming
MEK-remmers
MEK-remming
melanoma
melanoma brain metastases
melanoma in adolescents and young adults
melanoma in children and adolescents
melanoma of unknown primary
melanoma with rare BRAF mutations
melanoom
melanoom-geassocieerde leucoderma
melanoom-mortaliteit
melanoomrisico
melatonine
melfalan
melkconsumptie
MEN1
meningioma
meningioma risk factors
meningioom
menopausal hormone therapy options
menopauzale hormoontherapie
mental health disorders
mental health of mothers and siblings
mentale stoornis
Merkel celcarcinoom
Merkelcelcarcinoom
MESCC
mesothelin-targeted CAR T cells
mesothelioom
mestcel-neoplasmata
MET exon 14 altered lung cancer
MET-amplificatie
meta-analysis
meta-analysis of outcomes
meta-analysis of studies of immunotherapy for NSCLC
metabole gezondheid
metabolic dysregulation
metabolic health
metabool syndroom
metastase
metastasectomie
metastasering
metastasevrije overleving
metastasis-directed therapy
metastasis-free interval
metastatic breast cancer
metastatic breast cancer in geriatric patients
metastatic cardiophrenic lymph nodes
metastatic castration-resistant prostate cancer
metastatic castration-sensitive prostate cancer
metastatic colorectal cancer
metastatic colorectal cancer cetuximab plus FOLFOX-4
metastatic colorectal cancer in older vulnerable patients
metastatic esophageal cancer
metastatic esophagogastric adenocarcinoma
metastatic esophagogastric cancer
metastatic gastric cancer
metastatic gastric or gastroesophageal junction cancer
metastatic gastric or junctional adenocarcinoma
metastatic gastrointestinal tract cancer
metastatic HER2-positive breast cancer
metastatic hormone-sensitive prostate cancer
metastatic intrahepatic cholangiocarcinoma
metastatic melanoma
metastatic MSI-H dMMR CRC
metastatic mucosal melanoma
metastatic nasopharyngeal carcinoma
metastatic non-small cell lung cancer
metastatic nonsquamous NSCLC
metastatic osteosarcoma
metastatic pancreatic adenocarcinoma
metastatic pancreatic cancer
metastatic pancreatic ductal adenocarcinoma
metastatic prostate cancer
metastatic renal cell carcinoma
metastatic spinal canal compression
metastatic squamous NSCLC
metastatic triple-negative breast cancer
metastatic urothelial carcinoma
metastatic uveal melanoma
metastatisch castratieresistent prostaatcarcinoom
metastatisch cervixcarcinoom
metastatisch colorectaalcarcinoom
metastatisch colorectaalkanker
metastatisch colorrectaalcarcinoom
metastatisch heldercellig niercelcarcinoom
metastatisch maagcarcinoom
metastatisch mammacarcinoom
metastatisch melanoom
metastatisch niercelcarcinoom
metastatisch niet-castratieresistent prostaatcarcinoom
metastatisch pancreas ductaal adenocarcinoom
metastatisch pancreascarcinoom
metastatisch PDAC
metastatisch potentieel
metastatisch prostaatcarcinoom
metastatisch squameus celcarcinoom van hoofd en hals
metastatische borstkanker
metastatische botziekte
metastatische castratieresistente prostaatkanker
metastatische colorectaalkanker
metastatische niet-kleincellige longkanker
metastatische prostaatkanker
metastatische triple-negative borstkanker
METEOR
METEOR-studie
metformin
metformin plus CRT
metformine
methionine
methotrexate neurotoxicity
metronome chemotherapie
metronomic methotrexate-celecoxib-erlotinib
METROS study
MF
mFOLFOX6
MGPT
MGUS
MHD
mHNSCC
MHSs
MHT
MIBC
MIC-1
microductectomy
microRNA-203
microRNA-371a-3p test
microRNA-classifier
microRNAs
microsatelliet-instabiele kanker
microsatellite instability
microsatellite instability-high mCRC
middel-heupomtrekverhouding
middelomtrek
middelomvang
midgut NETs
migraine
migratie naar hersenparenchym
MILD trial
MILES-3
MILES-4
million women study
MILS
MINDACT
mindfulness
mindfulness-based cognitive therapy
minimal residual disease
minimally invasive robotic surgery
minimally invasive versus open surgery
mipsagargin
MIPSS70
miR-126
miR-190b
miR-34
miR-345
miR-506
miRNA
miRNAs
MIRO-studie
mismatch repair status
Mitchell
MITCI-studie
MITO-8 studie
MITO-9 study
mitomycin C
mitosesnelheid
mitotische activiteitsindex
mitoxantrone
MK-2206
MK-3475
MLBO
MM
MM-302
MMR
MMR-D noncolorectal cancers
MMR-deficiency
MMR-deficiëntie
MMSE
mNPC
mNSCLC
MNTX
mode of detection
mode of progression
moderately hypofractionated helical IMRT
moderately hypofractionated IMRT
modern chemotherapy
mogamulizumab
Mohs surgery versus wide margin excision
moleculaire subtypen
moleculaire tumormarkers
molecular classification
molecular markers of prognosis
molecular markers of recurrence
molecular profiling
molecular relapse detection
molecular subtypes
molecular subtypes of breast cancer
Molina
MONALEESA-2 studie
MONALEESA-7 studie
MONALEESA-7 trial
MONARCH 1
MONARCH 1-studie
MONARCH 2 study
MONARCH 2-studie
MONARCH 3-studie
mondholte squameus celcarcinoom
mondholtecarcinoom
mondhygiëne
mondkanker
monoclonal antibody combined with induction chemotherapy
monoklonale B-cel lymfocytose
Moore-criteria
morcellatie
mortaliteit
mortaliteit colorectaalcarcinoom
mortaliteit na kankerdiagnose
mortality
mortality after breast cancer
mortality as function of age
mortality from unrelated causes
mortality prediction by Oncotype DX
mortality trends
mortalteit
MOSAIC
MOSAIC trial post hoc analysis
moxetumomab pasudotox
mPCa
mPDAC
MplBC
MPM
MPN
MPNs treated during pregnancy
mRCC
MRD-status
MRD-stratified treatment
mRECIST objecte response
MRI
MRI background parenchymal enhancement
MRI plus targeted biopsy versus systematic biopsy alone
MRI staging of breast camcer
MRI-FIRST study
MRI-screening
MRI-screening mammacarcinoom
MS2010 study
MSC
MSE
MSG-carcinomen
MSI
MSI-CRC
MSLCs
MSLT-II studie
MT-GCT
MTC
mtDNA
MTH1-remmers
mTNBC
mTOR-remmer
mTOR-remmers
mUC
MUC16 mutations
mucosaal melanoom
mucosalaesies
mucositis
mucositispijn
mulitpel myeloom
Müllerian carcinoom
multi-gen panel testing HBOC
multidisciplinary salvage treatment
multidrugresistentie
Multiethnic Cohort
multigene testing for all patients
multikinase inhibitors
multimodal therapy
multipel myeloom
multipel myeloom. KTd
multipele endocriene neoplasie
multiple foci of microinvasion
multiple myeloma
multiple myeloma refractory to CD38 MoABs
MULTOMAB study
MURANO study
MURANO-studie
muscle-invasive bladder cancer
musculoskeletal burden
mutatiescreening
mutatievolgorde
mutation burden
mutation clearance
mutation profiling
mutation status and prognosis
mutations in cancer-associated genes
mutations in cancer-related genes
mutp53 proteins
muziektherapie
MVAC
MVPA
MYC
MYC rearrangement and translocation partner
Myc-remming
MYCN
mycosis fungoides
myelodysplasie
myelodysplastic syndrome
myelodysplastisch syndroom
myelodysplastisch syndroom myeloproliferatieve neoplasmen
myelodysplastische syndromen
myelofibrose
myelofibrosis
myeloid malignancies
myeloïde neoplasie
myeloma
Myeloma X trial
Myeloma XI study
myeloom
myelopreservation with trilaciclib
myeloproliferatieve neoplasmen
MYL-14010
myocarditis
myomectomie
MyPathway study
MyPathway-studie
myxoid liposarcoma
MZL
n-3 fatty acids
N-cadherine
N1087-studie
N3 stage IIIB NSCLC in elderly patients
NA-PHER2 studie
Naakte molrat
nab-paclitaxel
nab-paclitaxel plus gemcitabine
nab-paclitaxel plus gemcitabine plus cisplatin
NABON Breast Cancer Audit
nachtarbeid
NACT
naevi
NALA study
nanoparticles
nanotechnologie
NAPOLI-1 study
NAS
nasofarynxcarcinoom
nasopharyngeal cancer
nasopharyngeal carcinoma
National Breast and Cervical Cancer Early Detection Program
National Cancer Data Base
National Cancer Database analysis
National Institute for Health and Care Excellence
National Lung Cancer Screening Trial secondary analysis
natriumthiosulfaat
natural killer
natural killer T-cel lymfoom
NBTXR3
NC-6004
NCCN-richtlijnen
NCGA
NCGC
NCI 8628
NCI-CONNECT
NCI-Maryland Case Control Study
NCI-MATCH study
NCI-Match Trial E131-Y
NCI9673
NCIC CTG MA.27-studie
NCM
NCSLC
NDMM
NEC study
NECC
necitumumab
negative colonoscopy
negative for intraepithelial lesions or maligancy
negative thyroid biopsy
NEJ009 study
nelfinavir with concurrent chemoradiotherapy
NELM
NELSON-studie
NEMO
NENs
neoadjuvant anti-HER2 therapy for HER2-positive breast cancer
neoadjuvant aspirine
neoadjuvant bevacizumab
neoadjuvant CAPOX plus radiotherapy
neoadjuvant carboplatin plus docetaxel
neoadjuvant chemoradiation
neoadjuvant chemoradiotherapy
neoadjuvant chemotherapy
neoadjuvant durvalumab
neoadjuvant endocrine versus chemotherapy
neoadjuvant erlotinib
neoadjuvant FOLFIRINOX
neoadjuvant FOLFIRINOX or gemcitabine plus nab-paclitaxel
neoadjuvant gemcitabine plus S-1
neoadjuvant immune checkpoint blockade
neoadjuvant lapatinib plus trastuzumab without chemotherapy
neoadjuvant larotrectinib
neoadjuvant nab-paclitaxel
neoadjuvant pertuzumab
neoadjuvant plus adjuvant erlotinib
neoadjuvant radiotherapy
neoadjuvant SABRT
neoadjuvant T-DM1 plus lapatinib plus paclitaxel
neoadjuvant talazoparib
neoadjuvant therapy
neoadjuvant trastuzumab emtansine plus pertuzumab
neoadjuvant trastuzumab plus pertuzumab
neoadjuvant zoledronic acid
neoadjuvante chemotherapie
neoadjuvante CRT
NeoALTTO
NeoCombi study
neonatal inflammatory markers
neonatal phototherapy
NeoPAL study
NeoPalAna
neoplasm risk
neopterine
NEOZOTAC trial
nephrectomy
nephrotoxicity
neratinib
nercelcarcinoom
NET
NETs
network meta-analysis of first-line treatments
neurale invasie
neuro-endocrien carcinoom
neuro-endocriene neoplasmen
neuro-endocriene tumoren
neuroblastoma
neuroblastoom
neurocognitie
neurocognition
neurocognitive function
neuroendocrine prostate cancer
neuroeondocriene tumoren
neurofibromatose
neurofibromatose 1
neurologic disorders
neuropathie
neuropsychiatric functioning
neuropsychological outcomes
neutrofiel lymfocyt-ratio
neutrofiel-lymfocyt ratio
neutropenie
neutrophilia
new treatment options
newly diagnosed APL
newly diagnosed cancer patients
newly diagnosed CML
newly diagnosed endometrial cancer
newly diagnosed glioblastoma
newly diagnosed multiple myeloma
newly diagnosed or relapsed multiple myeloma
newly diagnosed transplant-ineligible multiple myeloma
next-generation flow cytometry for assessing measurable residual disease
next-generation sequencing
next-generation sequencing of ctDNA
NF1
NF1 mutations
NF2
NFκB
NGS
nHL
NHL-001 study
NHS
NIBIT-MESO-1 studie
nice-or-naughty theorie
nicotine
niercarcinoom
niercelcarcinoom
niercelkanker
nierfunctie
niet-cervicale anogenitale maligniteit
niet-chirurgische behandeling
niet-invasief prenataal testen
niet-kelincellig longcarcinoom
niet-kleincellg longcarcinoom
niet-kleincellig longcarcinoom
niet-kleincellige longkanker
niet-melanoom huidkanker
niet-seminomateus testiscarcinoom
niet-squameus niet-kleincellig longcarcinoom
nieuw logo
Nieuw-Zeeland
NIFTP
night shift work
NIH-AARP
NIH-AARP Diet and Health study
NIH-AARP Diet and Health Study; alcohol consumption
NILM
NiloPeg
nilotinib
nimotuzumab
nintedanib
nipple-sparing mastectomy
NIPPON DATA 80
niraparib
niraparib after response to chemotherapy
niraparib maintenance
niraparib plus pembrolizumab
nitraat
nitriet
nivolumab
nivolumab for advanced cancer
nivolumab plus ipilimumab
nivolumab plus ipilimumab versus sunitinib
NIVOREN study
NK
NLCS
NLPHL
NLR
nmCRPC
NMIBC
NMR
NMSC
NMSC-ASE
NMSIs
NNAL
NO16968
NO2
NOA-07 studie
NOCCA study
nodal PTCL
node-positive breast cancer
nodulair lymfocyt-predominant Hodgkin lymfoom
NOM
non-alcoholic fatty liver disease
non-engineered multi-antigen specific T cells
non-germinal center B-cell DLBCL
non-germinal center B-cell like diffuus grootcellig B-cel lymfoom
non-Hodgkin lymfoom
non-Hodgkin lymphoma
non-inferioriteits fase 3-studie AXEPT
non-melanoma skin cancer
non-metastatic castration-resistant prostate cancer
non-muscle-invasive bladder cancer
non-relapse mortaliteit
non-RMS soft tissue sarcoma in patients younger than 30 years
non-seminoom testikelkanker
non-small cell lung cancer
non-small cell lung cancer surgery
non-specific symptoms and signs of cancer
non-squamous metastatic non-small cell lung cancer
non-V600 BRAF mutations
nonadherence
nonadherence to cancer screening
nonaspirin NSAIDs
noncancer mortality
noncolorectal dMMR MSI-H cancers
nongerminomatous malignant germ cell tumors
nonhereditary breast cancer
noninferiority phase 3 study HYPO-RT-PC
nonmelanoma skin cancer
nonmetastatic breast cancer
nonverbale communicatie
Noorwegen
NOPHO ALL2008 protocol
NOPHO ALL2008 study
NORCCAP-studie
Nordic Lymphoma Group
NORDIC9 study
not transplant-eligilbe MM
NOx
NPC
NPM1-gemuteerde AML
NRAS-mutatie
NRAS-mutaties
NRF2 expression
NRG Oncology RTOG 1203
NRG Oncology RTOG studie 0621
NRG-GY003
NSABP B-28 studie
NSABP B-31 study
NSABP B-40
NSABP B-41 neoadjuvant trial
NSABP B-42
NSABP B-42 study
NSABP FB-10 trial
NSAID
NSAID-gebruik
NSAIDs
NSCLC
NSCLC brain metastasis
NSCLC in postmenopausal women
NSCLC progressing on various EGFR TKIs
NSCLC refractory to second-generation ALK inhibitor
NSCLC with ALK or ROS1-rearrangement
NSCLC; linifanib
NSGCT
NSM
nsq NSCLC
nsq-NSCLC
NTD-Haplo versus SUCBT
nucleaire installaties
nuclear ZEB2 expression
Nurses' Health Study
Nurses’ Health Studies
Nurses’ Health Study
Nurses’ Health Study I and II
Nurses’ Health Study II
nursing home residents
nut consumption
nutrient intake
NutriNet-Santé cohort
NutriNet-Santé prospective cohort
NutriNet-Santé studie
NutriNet-Santé study
nutritional status
NWAS
NWTS-5
OA-MCL
OAC
OAK
OAK-studie
obesitas
obesitasparadox
obesity
obesity-related cancer trends
obinutuzumab
obinutuzumab plus lenalidomide
Observationele studie van discontinueren van TKIs voor CML in de Italiaanse klinische praktijk
obstetric and maternal outcomes
obstetric outcomes
OCC
OCCC
occult breast cancer
occulte kanker
occupational variation
OCSCC
ocular toxicity of bortezomib
ODM-201
odontoom
ODXRS
oedeem
oesofagaal squameus celcarcinoom
oesofagastrische tumoren
oesofagectomie
oesofagogastrisch adenocarcinoom
oesofagus squameus celcarcinoom
oesofagusadenocarcinoom
oesofaguscarcinoom
oesofaguskanker
oesophageal squmous cell carcinoma
oestradiol
oestrogeengebruik
oestrogeenreceptor
oestrogeensuppressie
ofatumumab
offspring donors versus HLA-matched siblings
offspring of survivors of childhood or adolescent CNS tumors
OGC
OHERA study
Okayama Lung Cancer Study Group Trial 1404
olanzapine
olaparib
olaparib maintenance
olaparib plus cetuximab and IMRT
olaparib plus temozolomide combination
older adults with cancer
older breast cancer patients with high recurrence scores
olfactorisch neuroblastoom
oligometastase
oligometastatic cancer
oligometastatic cancers
oligometastatic non-small cell lung cancer
oligometastatic NSCLC
OLIVIA
OlympiAD-studie
OM-CRC
omacetaxine mepesuccinate
omega 3-vetzuren
OMEGA offspring cohort
omission of dexamethasone
ONC201
oncolytisch adenovirus
oncolytische virustherapie
oncoplastische mammoplastie
Oncoscience
Oncotype
Oncotype DX
Oncotype DX DCIS-score
ondergewicht
onderhoudstherapie
ondervoeding
onderzoeksfraude
one week off
ONJ
ONT-380
ontstaan colorectaalkanker
ontwikkeling resistentie
oogmelanoom
Oost-Afrika
OPAS-1 study
OPC
open resectie
open versus minimally invasive surgery
opioid use
opioid use among older cancer survivors
opioid use and toxicity among cancer survivors
opleidingsniveau
OPN
OPSCC
opsoclonus-myoclonus ataxie syndroom
OPTIMA Prelim
optimal RT strategy after breast-conserving surgery
optimal sequence of enzalutamide and abiraterone acetate plus prednisone
OPTIMISMM study
optimizing chemotherapy
OPTION-studie
Opto-RTKs
oraal carcinoom
oraal oncogeen HPV
oral androgen signaling inhiibitos
oral arsenic trioxide
oral cavity or oropharyngeal squamous cell carcinoma
oral cavity squamous cell carcinoma
oral endocrine therapy
oral health
oral hydration after cisplatin
oral mucositis after chemoradiotherapy for OCC OPCC
oral S-1
orale anticonceptiva
orale contraceptiva
ORATOR study
ORCA-010
ORCHARRD
orgaantransplantatie
Organ transplant recipients
organ-sparing transanal endoscopic microsurgery
organic food consumption
organische oplosmiddelen
orgnnoïdencultures
ORIENT-1 study
orofaryngeaal squameus celcarcinoom
orofarynx squameus celcarcinoom
orofarynxcarcinoom
oropharyngeal cancer
oropharyngeal HPV infections
orthopedische oncologie
OS
OS2006 Sarcome-09 study
OSCC
osimertinib
OSJ
Oslo 1-studie
OSLO-COMET study
osteonecrose van de kaak
osteopenie
osteopontin
osteoporosis
osteosarcoma
osteosarcoom
ototoxiciteit van chemotherapie
OTX015
outcomes
outcomes of surgery
outcomes without locoregional treatment
OV21 PETROC
ovarian cancer
ovarian cancer risk
ovarian function
ovarian function suppression
ovarian stimulation
ovarian tumors
ovariëctomie
ovariumcacrinoom
ovariumcarcinoom
ovariumfunctie
ovariumfunctie-suppressie
ovariumfunctiesuppressie
ovariumkanker
ovariumtumoren
ovariumvolume
OVC
overall mortality in men versus women
overall survival
overall survival-analyse van fase 3-studie ARCHER 1050
overdiagnose
overdiagnosis
overgewicht
overhospitalisatie overlevers
overlevers jeugdkanker
overlevers kinderkanker
overleving
overleving borstkanker
overleving CRC
overleving in Europa
overleving melanoom
overleving oudere patiënten
overweight
oviductcarcinoom
oxaliplatin
oxaliplatin-based adjuvant chemotherapy
oxaliplatine
oxybutynin
p16 Ki-67 dual stain and HPV16 18 genotyping
p53
PABC
PACE-B study
PACE-studie
pachymeningeal seeding
PACIFIC study
PACIFIC-studie
paclitaxel
PACMEL trial
PACT-15 studie
PACT-19 study
PADT
Painyanitikul
PALB2 germline mutations
PALB2-mutatie
PALB2-mutaties
palbociclib
palliatie
palliatieve radiotherapie
PALOMA-1 TRIO-18
PALOMA-2 analyse
PALOMA-3
PALOMA-3 study
PAM50 signature
PAMELA
PAMELA-studie
pamiparib plus tislelizumab
pan-cancer noninvasive detection of MSI and high TMB
pan-RAF remmers
PANACEA study
pancreas
pancreas cancer
pancreas ductaal adenocarcinoom
pancreas-adenocarcinoom
pancreas-ductaaladenocarcinoom
pancreas-MCNs
pancreasadenocarcinoom
pancreascarcinoom
pancreaskanker
pancreatectomie
pancreatic adenocarcinoma
pancreatic cancer
pancreatic cancer risk
pancreatic cystic neoplasms
pancreatic ductal adenocarcinoma
pancreatic fistula
pancreatic NETs
pancreatic-colorectal-stomach cancer
pancreaticoduodenectomie
pancreaticoduodenectomy
PANFIRE
PANFIRE-2 study
panitumumab
panobinostat
PANVAC
papillair craniofaryngioom
papillair metastatisch niercelcarcinoom
papillair schildkliercarcinoom
papillary neoplasms of the breast
paraganglioma
paraneoplastisch neurologisch syndroom
Parkinson
PARP-remmer
PARP1-expressie
partial prostate treatment
partial versus whole breast irradiation
particpating in randomized breast cancer study
PAs
passief roken
PASSOS Heart studie
pathogenic germline variants
pathogenic variants in less familiar cancer susceptibily genes
pathological nipple discharge
pathologically node-negative neck
patient reported outcome
patient reported outcomes
patient reported symptoms
patient volume of oncologist
patient- and clinican-reported
patient-collected versus clinician-collected samples
patiënt-gerapporteerde uitkomsten
patient-reported outcomes
patiëntnavigatie
patients aged 40 years or younger
patients younger than 50 years
patterns of recurrence
patterns of relapse after neoadjuvant chemotherapy in clinical practice
PAVO study
pazopanib
pazopanib plus cetuximab
PBC
PBL
PBSO
PBT
PC
PCa diagnosis
PCD
PCI
PCLO
PCNSL
PCOS
pCR
pCR and outcomes by intrinsic subtypes of breast cancer
pCR to NACT
pCR to pertuzumab and trastuzumab
PCSNL
PD-(L)1-blockade
PD-1
PD-1 Ab
PD-1 and PD-L1 inhibitos
PD-1 blockade
PD-1 inhibitor
PD-1 inhibitors for mNSCLC
PD-1 PD-L1 inhibitors
PD-1-inhibitor therapy
PD-L1
PD-L1 expression
PD-L1 expression as predictive biomarker
PD-L1-positive advanced NSCLC
PD-L1-positive mTNBC
PDAC
PDS
PDT
PEAK study
pediatric acute leukemia
pediatric ALL
pediatric AML
pediatric and youg adult cancer surivors
pediatric brain tumor survivors
pediatric cerebral microbleeds
pediatric CT-related radiation exposure
pediatric germ cell tumors
pediatric hepatoblastoma
pediatric locally advanced TRK fusion sarcomas
pediatric low-grade glioma
pediatric medulloblastoma
pediatric neuro-oncology
pediatric neuroblastoma
pediatric or adolescent NHL
pediatric Ph+ CML-CP
pediatric posterior fossa tumors
pediatric R R ALL
pediatric recurrent ependymoma
pediatric relapsing high-risk ALL
pediatric thyroid cancer incidence and mortality trends
pediatrisch ALL
pediatrisch AML
pediatrisch ependymoom
pediatrisch sarcoom
pediatrische AML
pediatrische CNS-tumoren
pediatrische hersentumoren
pediatrische leukemie
pediatrische NETs
pediatrische patiënt-gerapporteerde uitkomsten
pediatrische stamceltransplantatie
PEG
PEG-IFN
pegfilgastrim
pegfilgrastim-profylaxe
pegilodecakin
pegteograstim
pelareorep
pelvic radiotherapy
pelvic RT versus IMRT
pembolizumab
PEMBRO-RT study
pembrolizumab
pembrolizumab after locally ablative therapy
pembrolizumab for advanced melanoma
pembrolizumab for advanced NSCLC
pembrolizumab for advanced prostate adenocarcinoma
pembrolizumab for previously treated mTNBC
pembrolizumab for previously untreated
pembrolizumab plus axitinib
pembrolizumab plus RT after induction chemotherapy
pembrolizumab versus best supportive care for advanced HCC
pembrolizumab versus ipilimumab
pemetrexed plus carboplatin
pemetrexed plus cisplatine
penta-refractory MM
peptide receptor radionuclide therapy
percentage dense area
perception of cancer risk
percutaneous ablation
percutaneous IRE
PerELISA neoadjuvant study
perfluarinated alkylated substances in serum
perifeer T-cel lymfoom
perifere neuropathie
perinatal outcomes
periodontale ziekte
perioperative cell-free DNA dynamics
perioperative dynamic changes in ctDNA
perioperative FLOT versus ECF ECX
perioperative radiotherapy
peripheral T-cell lymphoma
peritoneal mesothelioma
peritoneal metastases from gastric cancer
peritoneale carcinomatose index
peritoneale metastasen
PERSEPHONE trial
PERSIST-1
PERSIST-2 studie
PERSIST-5 trial
persistent acromegaly
persistent postchemotherapy alopecia
persistente pijn
personalized ctDNA profiling
PERTAIN study
pertuzumab
pertuzumab plus trastuzumab
peru
PERUSE study
pesticide exposure
PET
PET CT
PET-CT
PET-CT staged localized follicular lymphoma
PET-guided risk adapted treatment
PET-guided treatment
PETAL-studie
PETHEMA GEM2012 study
peulvruchten
pevonedistat
pexidartinib
PF-05280014
PFS
PFT
PGC-1α
PGF
PGHD
PGT
Ph- ALL
Ph-ALL
Ph-like ALL
Ph-negative ALL in older patients
Ph+ ALL
phase 2 BENEFIT trial
phase 2 GEMCAD 1402 study
phase 2 study JULIET
phase 3 KEYNOTE-062 study
phase 3 NEJ026 study
phase 3 study AML08
phase 3 study COMBI-AD
phase 3 study TRAIN-2
phase 3 study TRIBE 2
phase 3 trial RADAR
phase III POLO trial
Phc
pheochrmocytoma
pheochromocytoma
PHEREXA-studie
Philadelphia chromosome-negative ALL
Philadelphia-negative B-cell ALL
PHILEMON-studie
PHOENIX study
PHP-Mel
physical activity
physical activity during adolescence
physican workforce requirements
physicians’ perspectives
PI3K mTOR-remming
PI3K-signalering
PI3Kδ
PIB
PICN
pictilisib
pigmented skin lesion classification
pijnlijke botmetastasen
PIK3CA
PIK3CA-altered HNSCC
PIK3CA-mutaties
pilaralisib
pilocarpine
pimecrolimus
pioglitazon
pituitary macroadenomas
pituitary metastasis
PIVOT-studie
pixatimod plus nivolumab
PL
placebo adverse events in cancer trials
PLACOL-studie
plasma-based genotyping
plasma-biomarkers
plasmacarotenoïden
platinum exposure
platinum-pemetrexed
platinum-refractory early failure oral cancer
platinum-resistant ovarian cancer
platinum-resistente ovariumkanker
PLATO study
plaveiselcelcarcinoom
PLCO cancer screening trial
pleiomorf lobulair mammacarcinoom
pleister
pleural mesothelioma
pleurectomie
pleurectomy decortication
PLGA
PLGG
ploegendienst
PLP
PLR
PLRG Observational Study
PM
PMBCL
PMF
PMRT
PN
pnacreascarcinoom
pNET
pneumonitis
PO-IMRT versus PPLN-IMRT
POD24
POEMS final analysis
Poland
polatuzumab vedotin
POLE-mutaties
POLLUX-studie
POLO study
polo-like kinaseremmer
poly-G repeats
polycyclische aromatische koolwaterstoffen
polycystische nierziekte
polycythemia vera
polyfarmacie
polymerase theta
polymorfismen
polypectomie
polypharmacy
polypose
pom-dex
pomalidomide
ponatinib
pooled analysis
population-based treatment patterns and survival
population-level survival
PORT
PORTEC-3
PORTOS
POSH-studie
positive initial margins
positive margins
post hoc analyse ASPIRE-studie
post hoc analyse FIRST-studie
post hoc analyse KEYNOTE-001 studie
post hoc exploratieve analyse RAISE-studie
post-hoc analyse PETACC-8 studie
post-hoc analyse REACH-studie
post-mastectomie radiotherapie
post-progression outcomes
post-transplantie lymfoproliferatieve ziekte
postdiagnostic calcium intake
postembolization syndrome
postmastectomy radiotherapy
postmenopausal advanced HR-positive breast cancer
postmenopausal bleeding
postmenopausal breast cancer
postmenopausal cancer
postmenopausal CRC risk
postmenopausal early-stage breast cancer
postmenopausal HR+ HER2- metastatic breast cancer
postmenopausal women
postmenopauzaal mammacarcinoom
postmenopauzaal mammarcinoom
postmenopauzale borstkanker
postmenopauzale hormoontherapie
postmenopauzale vrouwen
postoperatieve mortaliteit
postoperative mortality
postoperative radiation field
postoperative seizures
postoperative SRS
postoperative surveillance
posttraumatische stressstoornis
potentially modifiable risk factors
power morcellation
poziotinib
PPAR-gamma
PPIs
PR status
PR-status
PR1
PRACTICAL-studie
PrCa
PRCC
pre- and post-diagnosis smoking
pre-BCS MRI
pre-leukemisch
PRECIS study
precisie-oncologie
precisietherapie
precision medicine
PRECISION-studie
prediabetes
prediagnostic bile acid levels
prediagnostic telomere length
PREDICT
predicting chemotherapy benefit
prediction model
prediction of AML risk in healthy individuals
prediction of outcome
prediction of progression
prediction of response to anti-PD-1 therapy
predictions for 2019
predictive role of frameshift mutations
predictive role of tumor infiltrate
predictive value of SNP-signature for recurrence
predictors of outcome of HCT
predictors of recurrence
predictors of reponse to immune checkpoint inhibitors
predictors of response to anti-PD-1 PD-L1 therapy
predictors of survival
predictors of uptake of CPM
preëclampsie
preexisting antibodies
preexisting pain
PREF ALL
pregabalin
pregnancy
pregnancy after cancer diagnosis
pregnancy duration
pregnancy outcomes
pregnancy-associated breast cancer
pregnancy-associated cancer
prehabilitatie
prehabilitation
preïmplantatie-genetische diagnose
premature menopauze
premenopausal breast cancer
premenopausal breast cancer risk
premenopausal HR-positive HER2-negative metastatic breast cancer
prenatale blootstelling
prenatale carcinogenenblootstelling
preoperatieve chemotherapie
preoperatieve MRI
preoperatieve radiotherapie
preoperatieve radiotherapie voor rectumkanker
preoperative adverse event risk index for head and neck cancer surgery
preoperative anemia
preoperative elevated tumor markers
preoperative embolization
preoperative MRI
preoperative PET CT
preoperative risk evaluation
Preoperative-Palbociclib studie
PRESSING panel mutations
preterm birth
pretreatment vitamin D deficiency
PREVAIL-studie
prevalence of clinical diagnosis of ADHD
prevalence of HBV
preventie
preventie cervixkanker
preventie mammacarcinoom
prevention of early menopause
preventive drugs in the last year of life
previously treated advanced cervical cancer
previously treated advanced KRAS-mutated NSCLC
previously treated advanced NSCLC
previously treated small-cell lung cancer
previously treated solid tumors in children and young adults
previously untreated AML
prijzen medicatie
PRIMA study
primair CNS-lymfoom
primair melanoom
primair urethracarcinoom
primaire borstkanker
primaire plasmacelleukemie
primary breast cancer treatment
primary care clinic appointment time
primary CNS lymphoma
primary debulking surgery
primary liver cancer
primary mediastinal large B-cell lymphoma
primary surgery
primary tumor location
primary tumor sidedness
primary versus acquired T790M mutatiion
PRIME study
PRINCIPAL study
PRO-CTCAE
PRO-IMPACT studie
PROACCT score
PRODIGE 20-studie
PRODRIGE18 study
PROFILE 1001 study
ProfiLER-studie
PROFILES registry
profylactic salpingo-oophorectomy
profylactische mastectomie
prognose
prognose luminal A
prognosis
prognostic and predictive relevance of CMSs
prognostic case volume thresholds
prognostic factors
prognostic impact of HR subtypes
prognostic implications
prognostic index
prognostic model
prognostic protein-based signature
prognostic relevance of 21-gene recurrence score
prognostic risk score
prognostic role in lung cancer
prognostic role of circulating cell-free DNA
prognostic role of hypoxia and angiogenesis
prognostic value of CTCs
prognostic value of depth of response
prognostic value of TILs
prognostication
prognosticators
prognostische biomarker
prognostische discordantie
prognostische test
prognostische tools mammacarcinoom
progress in cancer survival and incidence
progressievrije overleving
progressievrije overleving na 24 maanden
progression risk stratification
progressive glioblastoma
progressive MPM
projections until 2030
prolaris
prolonged infusion of low dose gemcitabine
PROMIS-studie
PROMISE-studie
promotie
PRONOPALL-studie
PROPHECY study
prophylactic chestwall irradiation
prophylactic contralateral breast irradiation
prophylactic cranial irradiation
PROREPAIR-B study
PROs
PROSELICA-studie
Prosigna
Prosigna risk of recurrence score
prospective genotyping
prospective validation Gail Model
PROSPER study
prostaatcarcinoom
prostaatcarcinoom. androgeendeprivatietherapie
prostaatkanke
prostaatkanker
prostaatkankermortaliteit
Prostaid
prostate cancer
prostate cancer aggressiveness
prostate cancer incidence and mortality
prostate cancer mortality
prostate cancer outcomes following solid-organ transplantation
prostate cancer prognosis
prostate cancer progression
prostate cancer risk
prostate cancer risk and mortality
prostate cancer treatments
prostate cancer; long-term follow up NRG RTOG 9413 study
prostatectomie
proteasome inhibitor
proteasoomremmer
ProtecT
PROTECT-1 en -2 studies
PROTECT-studie
proton beam radiation therapy
proton beam radiotherapy
proton therapy
proton versus photon radiotherapy
protonradiotherapie
protontherapie
proximal colon serrated neoplasia
proximal versus distal detection
PRT
PS
PSA
PSA bounce
PSA-recidief
PSA-screening
PSAD
PSCCB
pSmad2
PSN
psoriasis
psychiatric utilisation prior to cancer diagnosis
psycho-oncology
psychologic distress
psychological distress
PTBP1
PTC
PTCL
pten
PTEN-verlies
PTGS2
PTH
PTSD
pulmonaire metastasen
pulmonary fibrosis
purchase of antidepressants
PURE study
PURE-01 study
PUVA therapy
PV
PVRL
pyrotinib
pyrotinib plus capecitabine
Q-koorts
QNBC
QoL
QSkin-studie
QUADRA study
quality of life
quality-adjusted time without symptoms of progression or toxicity
QuANTUM-R study
QUAZAR AML-001 Maintenance Trial
QuiRedex
quizartinib
R M ACC
R M head and neck cancer
R R AML
R R AML MDS
R R cHL
R R CLL
R R DLBCL
R R FLT3-mutated AML
R R folliculair B-cell lymphoma
R R FTL3-mutated AML
R R HL
R R MF SS
R R MM
R R MZL
R R NHL
r r-AML
R-cadherine
R-CHOP
R-CHOP 14 versus 21 studie
R-CHOP-14
R2-CHOP
RAAS
race and risk of subsequent aggressive breast cancer
race and survival
race-based differences in survival
race-specific differences
radcial cystectomy
RADIANT-2
RADIANT-4
radiation to hypothalamus and pituitary
radiation-associated intracranial malignancy
radiation-induced cardiac toxicity
radiation-induced cystitis
radical hemi-thoracic radiotherapy
radical prostatectomy versus watchful waiting
RADiChol-studie
radioactief jodium
radioembolisatie
radiofrequency localization
radiofrequentie-ablatie
radiogenomics
radiojodium-refractair gedifferentieerd schildkliercarcinoom
radiologic complete response
radiomica
radiomics
radionecrosis
radiosurgery
radiotherapie
radiotherapy
radiotherapy-related heuropathic pain
radium 223
radium-223
radon
RAI for hyperthyroidism
RAINBOW-studie
RAINFALL study
ralimetinib
raloxifeen
ramucirumab
RANGE study
RANGE-studie
RAPID trial
rare cancers
rare CNS tumors
rare T cell lymphomas
rare versus common genetic variants
RARECAREnet
RAS alterations
RAS BRAF-wt metastatic colorectal cancer
RAS mutated MGMT methylated mCRC
RAS wild-type metastatic colorectal cancer
RAS wildtype metastatic colorectal cancer
RAS-mutaties
RASTEN-studie
rate of memory change
rate of occult contralateral nodal disease
rates of cancer and all-cause mortality
RCC
RCM
RD
re-excisie
re-testing predictive biomarkers in surgical specimens
REACH-2 study
readministration of anti-PD-1 or anti-PD-L1 after irAE
readmission
real world outcomes
real-world data
real-world outcomes
real-world survival
real-world treatment and survival
real-world use of EGFR TKIs
rEC
receptor status conversion following neoadjuvant chemotherapy
receptorstatusverandering
recidief
recidiefrisico
recidiefrisico ER-positief mammacarcinoom
recidiverend multipel myeloom
recidiverend of refractair ALL
recidiverend of refractair mantelcellymfoom
recidiverend of refractair multipel myeloom
recidiverend refractair mantelcellymfoom
recidiverend refractair multipel myeloom
recidiverend refractair PCNSL
recidiverende beroerte
recidiverende ER-positieve borstkanker
RECIST
recombinant poliovirus for recurrent glioblastoma
recombinant zoster vaccine
RECORD-2
recovery of ovarian function
rectal cancer
rectal cancer in elderly patients
rectumcarcinoom
rectumccarcinoom
rectumkanker
recurrence
recurrence in nipple-areola complex
recurrence of breast cancer
recurrence patterns
recurrence patterns after RT for brain metastases
recurrence predictive model
recurrent acute myeloid leukemia
recurrent advanced urothelial cancer
recurrent endometrial cancer
recurrent GBM
recurrent glioblastoma
recurrent glioma
recurrent hepatocellular carcinoma
recurrent high grade glioma
recurrent high-grade serous ovarian cancer
recurrent metastatic breast cancer
recurrent metastatic head and neck squamous-cell carcinoma
recurrent of refractory soldi tumors in children and adolescents
recurrent or metastatic HNSCC
recurrent ovarian cancer
recurrent platinum-resistant ovarian carcinoma
recurrent platinum-sensitive ovarian cancer
recurrent women’s cancers
recurring endometrial cancer
ReDOS study
reduced LVEF
reduced-dose fluoropyrimidine therapy
refractory large B-cell lymphoma
refractory mCRPC
refractory relapsed B-cell malignancies
refusal of conventional cancer therapy
refusal of surgery
regional lymph node irradiation
regional nodal irradiation
regional versus general anesthesia
regionale lymfeklierbestraling
REGOBONE study
REGOMA study
regorafenib
REGOSARC
rejection of systemic therapy
relapse
relapse after allogeneic stem-cell transplantation
relapse after autoSCT
relapse detection by routine CT scan versus symptoms
relapsed CLL
relapsed CLL SLL
relapsed follicular lymphoma
relapsed glioblastoma
relapsed multiple myeloma
relapsed or refractory B-cell ALL in children and young adults
relapsed or refractory classic Hodgkin lymphoma
relapsed or refractory classical Hodgkin lymphoma
relapsed or refractory indolent lymphoma
relapsed or refractory multiple myeloma
relapsed or refractory non-Hodgkin lymphoma
relapsed or refractory primary CNS or introcular lymphoma
relapsed or refractory solid tumors
relapsed ovarian cancer
relapsed platinum-sensitive ovarian cancer
relapsed refractory Hodgkin lymphoma
relapsed refractory multiple myeloma
relapsed refractory NHL
relapsed SCLC
relative dose intensity
relative lymphocyte count
RELAY study
RELAZA2 study
RELEVANCE trial
religieuze overtuigingen
REMAGUS02 study
remaining life expectancy
REMARC study
remming CD95-route
remming hedgehog-signaalroute
remnant liver ischemia
REMOTUX trial
renal cell carcinoma
renal function
RENO study
reovirus
repeat hepatectomy vs percutaneous radiofrequency ablation
repeat radiosurgery
repeat SRS
RERISE-studie
resectable lung SCC
resected ampullary carcinoma
resected biliary tract cancer
resected brain metastases
resected colorectal liver metastases
resected PDAC
resectie laaggradig glioom
resection
resection before immunotherapy
resection of brain metastases
residual cancer burden index
residual HER2-positive breast cancer
resiquimod
resistant starch
resistentie
RESONATE study
RESONATE-17
respiratory morbidity
respiratory outcomes
Response Assessment in Neuro-Oncology werkgroep
response to anti-EGFR therapy
response to HER2-targeted therapy
response to lung cancer immunochemotherapy
response to stereotactic radiosurgery
RESPONSE-2
response-based radiotherapy
RESTORE
Restoring Invisible and Abandoned Trials
results in North America
resumption of immune checkpoint inhibitor therapy
Ret
RET-fusion positive NSCLC
RET-rearranged lung cancer
retinoblastoom
retinol
retroperitoneaal sarcoom
retroperitoneal liposarcoma
retroperitoneal lymph node dissection
retroperitoneal sarcoma
retrospectieve analyse PETACC-3 studie
reumatoïde artritis
REVERCE study
reverse gene expression profiling
RFA
rhabdomyosarcoma
rhabdomyosarcoom
riboflavine
RIC alloHSCT
rich TILs
RICH-ART study
Richter transformation
RICMAC-studie
ridaforolimus
right-sided colon cancer
rilotumumab
RILT
rindopepimut
risedronaat
risico borstkanker
risicoscore
risicostratificatie
risk factors for cardiovascular disease
risk factors for depression and anxiety
risk factors for progression
risk of all cancer types
risk of breast cancer after breast radiation and anthracycline use
risk of cancer
risk of cardiovascular disease mortality
risk of cardiovascular hospitalization
risk of colorectal adenoma
risk of developing or dying of cancer
risk of glioma
risk of internal malignancies
risk of lethal prostate cancer
risk of lung
risk of malignancy
risk of malignant neoplasms
risk of preterm birth
risk of progression
risk of second cancer
risk of second event after DCIS
risk of secondary malignancies
risk of SMNs after treatment for testicular germ cell cancer
risk of subsequent cancers
risk of suicide
risk of suicide after cancer diagnosis
risk of testicular germ cell tumors
risk prediction model
risk stratification
risk-based treatment stratgy
risk-reducing salpingo-oophorectomy
rituximab
rituximab maintenance
rituximab plus lenalidomide
rituximab SC of IV
rivaroxaban
RMM
RMP
RMS 2005 study
RNA-disruptie
RNU2-1f
ROAR basket trial
robot-geassisteerde prostatectomie
rociletinib
roken
rolapitant
ROLARR-studie
ROMANA 3-studie
romidepsine
romiplostim
ROMULUS study
rookloze tabaksproducten
ROS-1 rearranged NSCLC
ROS1-positive NSCLC
ROS1-rearranged advanced NSLCL
ROSE TRIO-012
Ross
rotating night shift work
Rotterdam Study
Rova-T
RP-LPS
RPD vs OPD
rPFS
RPLMS
RPS
RR CLL SLL
rrHL
RRMM
rrPMBCL
RRSO
RRx-001
rs4143094
RT
RT after BCS
RT after complete response to ABVD
RT plus XRT
RT versus transoral robotic surgery
RTOG 0126-studie
RTOG 0214 study
RTOG 0521 study
RTOG 0617
RTOG 0813 trial
RTOG 1014 study
RTOG 1016 study
RTOG-0129 risk groups
RTSG-SIOP
RTW
rucaparib maintenance
ruxolitinib
ruxolitinib plus azacytidine
S-1
S-TRAC trial
S1P-antagonisme
SA
SABCS 2015
SABR
SABR-COMET study
SABRINA-studie
sacher
sacituzumab govitecan
sacituzumab govitecan-hziy
SACURA trial
SAFE-HEaRt study
safety of AA with glucocorticoids
safety of CRS HIPEC
SaGa
SAKK 35 10 trial
sALCL
salivary MECs
salpingectomie
SALTO-studie
salvage chirurgie
salvage re-irradiation
salvage treatment
salvage treatments
sAML
saracatinib
SARAH-studie
SARC024 study
SARC028-studie
sarcoma
sarcomatoid HCC
sarcoom
sarcopenia
sarcopenic patients
sASCT
sAxl
SBA
SBM
SBRT
SBRT schedule
SC
SC.23
scalp cooling
scalpmelanoom
Scandinavian HYPO-RT-PC study
SCC
SCCA
SCCAC
SCCHN
SCCOT
SCCUP
sCD23
schade kleine hersenvaten
schildkliercarcinoom
schildklierkanker
schildkliertumoren
schildwachtklier
schildwachtklierbiopsie
schildwachtlymfeklierbiopsie
SCIENTIFIC-studie
SCLC
SCORAD III-studie
SCORAD randomized trial
SCOT-studie
screen-detected vs non-screen-detected
screening
screening cervixcarcinoom
screening colorectaalcarcinoom
screening contralateraal mammacarcinoom
screening CRC tumors for Lynch syndrome
screening digital mammography
screening for pancreatic cancer
screening longcarcinoom
screening mammacarcinoom
screening mammography
screening ordering and completion
SCSHN
SDF1
SEAFOOD Polyp Prevention Trial
SEAL
second allo-HCT versus donor lymphocyte infusion
second cancers after radical treatment
second line FOLFIRI plus ramucirumab
second lumpectomy and reirradiation
second primary cancers
second primary NSCLC after HNC
second solid cancer outcomes
second-line binimetinib plus capecitabine
second-line CAPTEM versus FOLFIRI
second-line XELIRI versus irinotecan monotherapy
secondary analysis CONVERT study
secondary analysis of CheckMate 141
secondary MDS AML
secondary solid tumor malignancies
secondary surgical cytoreduction
secundaire analyse ATAC-studie
secundaire analyse AZURE-studie
secundaire analyse BIG 1-98 studie
secundaire analyse GOG-0218 studie
secundaire analyse GOG-210 studie
secundaire analyse LUX-Lung 8-studie
Secundaire analyse NSABP B-30
Secundaire analyse REVEL-studie
secundaire analyse van CANTOS-studie
Secundaire analyse van EF-14
secundaire analyse van EORTC 22952-26001
secundaire analyse van FAPEST-studie
secundaire analyse van GeparSixto
secundaire analyse van GOG-0218 studie
secundaire analyse van RTOG 9704-studie
secundaire analyse van STO-3 studie
Secundaire analyse van SWOG S0221
sedentaire tijd
SEER analysis
SEER database analysis
segmentectomie
SEHIB-studie
SEIPLUS study
seksueel functioneren
seksuele toxiciteit
SELECT trial
SELECT-1 studie
SELECT-D studie
selecteren van moleculair-geleide therapie
selectieve interne radiotherapie
seleen
Selenium and Celecoxib Trial
self-compression versus standard compression
SELHEM
selinexor
selinexor-dexamethasone
selumetinib
seminoom
SEMS
SenSzi study
sentinel
sentinel lymph node biopsy
sentinel lymph node detection
sentinel-node micrometastases
sepantronium bromide
sEpCAM
sequencing plasma cell-free DNA
sequential FOLFIRINOX and SBRT
sequential ICI and crizotinib
sequential PD-(L)1 blockade and osimertinib
sereus ovariumcarcinoom
serial imaging
SERM
serological markers of response
Sertoli-Leydig
serum assessment of non-adherence
serum hormones
serum proteomics
serum thiol levels
serum VEGF
serum vitamin E
serum-metaboloomprofiel
serum-microRNAs
serumlipidem
serumlipiden
SES
sex difference
sex differences in prognosis
sex disparity
sex-based heterogeneity
sex-linked differences
sexually transmitted infections
Sézary syndrome
Sézary syndroom
SGC
shared decision making
SHCC
short regimen of rituximab plus lenalidomide
Short-HER study
short-term mortality after starting chemotherapy
SHR-1210
SI-NETs
SIA
sidedness
sigaren
siglec
sigmoidoscopy screening
signifor
SILIUS trial
siltuximab
silver jk
simian virus 40
SIMONAL study
SIMPLICITY-studie
SIMPLIFY-1 studie
simulation of chemotherapy effects
Singapore Chinese Health Study
single dose HDR brachytherapy
single versus multiple primary melanomas
single-fraction SBRT vs multifraction conventional RT
single-fraction versus hypofractionated SRS
single-fraction versus multifraction RT
sinonasaal adenocarcinoom
sinonasaal carcinoom
sinonasaal melanoom
sintilimab
sirolimus
sirolimus versus prednisone
SIRveNIB-studie
Sister Study
Sisters Study
sites and sequence of metastases
six versus 12 months adjuvant capecitabine
skelet-gerelateerde gebeurtenissen
skeletal metastases
skeletal muscle loss
skin cancer
skin cancer incidence
skin cancer prevention
skin cancer risk
skin reaction
skull-base chondrosarcoma
slaapduur
sleep characteristics
SLL
SLN mapping versus lymphadenectomy
SLN-biopsie
SLN-status
SLNB
slokdarm adenocarcinoom
slokdarm squameus celcarcinoom
slokdarmadenocarcinoom
slokdarmcarcinoom
slokdarmkanker
slokdarmkanker; chemoradiotherapie
SM
SMAD4 loss
small lymphocytic lymphoma
small node-negative HER2-positive breast cancer
small-cell lung cancer
smeulend multipel myeloom
SMM
SMN
SMNs
smoking
smoking cessation
smoldering multiple myeloma
SNIPP study
snoRNAs
SNP
SNPs
SNPs correlated with sunitinib benefit
SNTI
SNUC
SOAR-studie
sociaal-economische status
Sociaaleconomische status
sociale media
soft tissue sarcoma
SOFT- en TEXT-studies
soft-tissue sarcoma
sojaconsumptie
SOLAR-1 study
SOLD-studie
SOLE-studie
solid cancer diagnosis
solid organ transplant
solid tumors
solid-organ transplant
solide maligniteiten
solide tumoren
solitair intrathyroïdaal papillair schildkliercarcinoom
solitary fibrous tumor
solitary pulmonary nodules
SOLO1 study
SOLO2 ENGOT-Ov21 studie
soluble immune checkpoint-related proteins
somatische variatie
somatostatin analogues
somatostatine-analogen
sorafenib
sorafenib for advanced HCC
sorafenib for HCC
sorafenib plus OME
sorafnib maintenance after allo-transplantion
SORAML
SORMAIN Trial
SOS-studie
sotatercept
SOX2
soy-based dietary supplements
SPARC
SPARTAN-studie
SPC
SPCG-4
special section of Supportive Care in Cancer
specific cardiovascular diseases
spectroscopie
sperm count
Spierinvasief blaascarcinoom
spinaal myxopapillair ependymoom
spinal metastases
spinal metastatic disease
spinale epidurale metastase
spinale metastase
spinale SRS
SPIONs
splanchnische veneuze trombose
splenisch DLBCL
splicing factor
SPMN
SPMs
spontane abortus
sporadic colorectal cancer
spread through air spaces
SPS
sputum miRNA
sqCLC
squameus celcarcinoom
squameus celcarcinoom van de mondholte
squameus celcarcinoom van de orofarynx
squameus celcarcinoom van hoofd en hals
squameus-celcarcinoom
squamous cell carcinoma
squamous cell carcinoma of head and neck
squamous cell carcinoma of the base of the tongue
squamous cell carcinoma with HRAS mutations
squamous NSCLC
SQUIRE-studie
SRCC
SRE
SREs
SRS
SRT
SRT versus ART
SS
SS MF
SSA
SSIs
SSTR2
St Jude Lifetime Cohort Study
St Jude Total Therapy Study 16
St. Jude Lifetime Cohort
stadium IV colorectaalcarcinoom
stadium IV-NSCLC
stage 0 to II breast cancer
stage 1 nonseminomatous GCTs
stage 1 NSCLC
stage 1A or 1B gastric cancer
stage 1A RCC
stage 1A uterine papillary serous cancers
stage 2 colorectal cancer
stage and grade I endometrioid endometrial cancer
stage at cancer diagnosis
stage I breast cancer in women 65 years and over
stage I NSCLC
stage I-II cutaneous melanoma
stage II colon cancer
stage II III gastric cancer
stage II III rectal cancer
stage II-IIIA NSCLC
stage III colon cance
stage III colon cancer
stage III gastric cancer
stage III inflammatory breast cancer
stage III NSCLC
stage III ovarian cancer
stage IIIA NSCLC
stage IIIA-N2 EGFR mutation-positive NSCLC
stage IIIB and IIIC melanoma
stage IIIB-C BRAF-V600 mutated melanoma
stage IV ALK rearranged NSCLC
stage IV breast cancer
stage IV breast cancer at diagnosis
stage IV NSCLC
stage IV TNBC
staged stereotactic radiosurgery
stamceltransplantatie
STAMPEDE
STAMPEDE study
standard-risk NDMM
stappenteller
START
statin use
statines
statins
statins and lethal prostate cancer
statistieken 2012
statistische genezing
STELLAR study
stem cell transplantation
stemmingsaandoeningen
stereotactic ablative radiotherapy
stereotactic body radiation therapy
stereotactic body radiation therapy plus systemic therapy
stereotactic body radiotherapy
stereotactic radiation
stereotactic radiosurgery
stereotactic RT versus WBRT for cystic or solid brain metastases
stereotactische lichaamsradiotherapie
stereotactische radiochirurgie
stereotactische radiotherapie
sterfte aan kanker
steroid refractory GVHD in children
sTILs
STO-3 trial long-term follow-up
Stockholm III
stoma
stomach and esophagus cancer
stomach cancer pooling project
stomatitis
Stop & Go study
STOP IMAPED study
stopping imatinib
STORM study
STORM Study part 2
straling
stratification of risk of distant metastasis and death
STREAM-studie
stroma-gerichte therapie
stromal tumor-infiltrating lymphocytes
stromale tumor-infiltrerende lymfocyten
STS
STSs
Studie-uitval
Study 19
STZ 5-FU
subcutaan trastuzumab
subcutaneous administration of daratumumab
subcutaneous versus intravenous PF-06801591
subcutaneous versus intravenous trastuzumab
subependymal giant cell astrocytoma
subgroep-analyse van METEOR-studie
subgroepanalyse ALEX-studie
subgroepanalyse GREEN study
subgroepanalyse MONALEESA-2 studie
subgroepanalyse van FIRE-3 studie
subgroepanalyses LUX-Lung studies
subgroepenanalyses CAIRO3
sublobar resection
subsequent cancer diagnoses
subsequent malignant neoplasms
subsequent neoplasms after a primary tumor
subsequent primary neoplasms
subsequent risk of CSCC
substratification
substudie ALTTO
substudie van TRYPHAENA
subtotal resection
subtype
subtype-specific CBC
subtypen
subtypen HER2-positieve borstkanker
subtypes
subtypes maagcarcinoom
subtypes mammacarcinoom
SUCCESS A
SUCCESS A trial
SUCCESS-C study
sugary drink consumption and risk of cancer
suïcide
sun exposure
suncreen use
sunitinib
sunitinib dose and schedule optimization
sunitinib for RCC
SUNSHINE trial
superficial basal-cell carcinoma
superior vena cava syndrome
supplemental MRI
suppressie ovariumfunctie
supraglottische-larynxcarcinoom
SUPREMO trial
surgery
surgery for head and neck cancer
surgery for non-palpable breast lesions
surgery versus active surveillance
surgery versus SBRT
surgical excision margin
surgical treatment
surgically treated brain metastases
surival
surrogate end points
SURTIME trial
surveillance
surveillance colonoscopy after advanced adenoma removal
surveillance for relapse
survival
survival after radical prostatectomy
survival after radiotherapy
survival after recurrence
survival by race ethinicity
survival in breast cancer
survival of advanced NSCLC
survival trends
survivin-expressie
survivors AYA cancer
survivors childhood ALL
survivors childhood and AYA cancer
survivors of childhood and AYA cancer
survivors of childhood cancer
survivors of childhood Hodgkin lymphoma
survivors of HPV-associated cancers
survivors of non-central nervous system tumors in childhood
survivors of pediatric CNS tumors
susceptibility gene mutations
SVCS
SVT
SWAN-studie
Swedish Breast Cancer Group 91 Radiotherapy studie
Swedish Multicenter Cohort Study
Swedish Obese Subjects study
SWISH-studie
SWITCH
SWOG 0777
SWOG 1200-studie
SWOG 1406
SWOG 80405
SWOG 9313 trial
SWOG S0337-studie
SWOG S0518
SWOG S0622
SWOG S0800
SWOG S0905
SWOG S1202-studie
SWOG-S0016
SWORD-studie
Sym004
symptomatic osteonecrosis
synchronous and lifetime brain metastases
synchronous bilateral breast cancer
synchronous stage IV anal canal squamous cell carcinoma
synoviaal sarcoom
synoviosarcoom
systemic therapy with or without local treatment
systemic treatment
systemische lupus erythematosus
systemische mastocytose
SystHER study
T Cell Project
t-APL
T-cadherin
T-cel acute lymfoblastische leukemie
T-cel lymfoom
T-cell lymphoblastic lymphoma
T-cellymfoom
T-DM1
T-DM1 plus neratinib
T-VEC
T1-T2 RCC
T2DM
TAA-Ts
TABEA
TAC
TACE
TACTOPS study
tagraxofusp
TAGS study
TAILOR trial
TAILORx analysis
TAILORx secondary analysis
TAILORx study
TAILORx-studie
talazoparib
talk-pleurodesie
tamilogene laherparepvec
tAML
tamoxifen
tandem autologous stem cell transplant
TAPS
TARDOX study
targeted agents
targeted alpha therapy
targeted exome next-generation sequencing
targeted intraoperative radiotherapy
targeted therapies
targeted therapy
targeted versus nontargeted therapy
targeting long-term non-attenders
TAS-102
TAS-102 Gastric Study subgroup analysis
TAS-114
taselisib
TATTON study
Taxaan resistentie
taxane chemotherapy
TAXYNERGY-studie
TAZ
TBCRC 022 study
TBCRC023 study
TBCRC026 study
TBISI
TC
TCF3-HLF positief ALL
TCH
tea intake
TEAL study
TEAM IIB
TEAM-studie
TEAMM study
TECHNO and PREPARE trials
Teenage and Young Adult Cancer Survivor Study
tele-oncologie
telemedicine
televisiekijken
telisotuzumab vedotin
telomeerlengte
telomeerziekten
telomerase-activiteit
temozolomide
temporal changes in survival
temporal muscle thickness
temporal trends
temsirolimus
ten-year results
ten-year update of CALGB 49907
tenofovir
tenosynovial giant cell tumor
tenosynovial giant-cell tumor
teratoma
terbinafine
TERRA-studie
TERT-mutatie
testicular cancer
testicular cancer in children and young adults
testicular cancer in the cisplatin era
testicular germ cell tumors
testikelkanker
testiscarcinoom
textbook outcomes of curative-intent resection
TFAP2C
tFL
TG4010
TGCT
TGF-βRII
TH-302
TH3RESA
thalidomide
The Multiethnic Cohort
thee
therapeutic options
therapeutische vaccins
therapietrouw orale hormonale behandelingen
therapy-related AML
therapy-related cardiac risk
thermal ablation
thermal ablation versus nephrectomy
thermale ablatie
thick melanoma
Thinking and Living With Cancer Study
thiopurine
thiotepa-busulfan-fludarabine conditioning
thorax-radiotherapie
thromboprofylaxis
thrombosis
thrombotic events
THRα2
thymoom
thymuscarcinoom
thyorid cancer surgery
thyroid cancer
thyroid nodules
Tian
TIC
TIL therapy
TILs
time between positive gFOBT and colonoscopy
time interval to biochemical failure
time series analysis
time to death
time to metastasis
time to treatment failure
time without symptoms or toxicity
time-to-surgery
timing of adjuvant therapy
timing of HPV16-E6 antibody seroconversion
timing of initiation of adjuvant chemotherapy
timing of local therapy
timing of MRD-negativity
timing of onset of irAEs
tinzaparine
tipifarnib
TIPN
tirlateraal retinoblastoom
tisagenlecleucel
tislelizumab
tisotumab vedotin
TITAN study
TITAN-studie
TIVO-3 study
tivozanib
TKI
TKI discontinuation
TKIs
TKIs with versus without metformin
TL
TMB
TMNs
TMW
TMZ
tnAcity-studie
TNBC
TNBC risk genes
TNFi
TNFα-remmers
TNT-studie
TOAD-studie
tomaten
tomosynthese
tomosynthesi
tongbasiscarcinomen
tonsilcarcinoom
tonsillaire
TOPARP-B trial
topisch fluorouracil
toripalimab
TORS
totaal lichaamsbestraling
totaal-vet
total neoadjuvant therapy
total versus cortical-sparing adenalectomy
totale lichaamsbestraling
totale mesorectale excisie
totale mortaliteit
totale overleving
TOURMALINE-MM3 study
toxiciteiten van oncologische behandelingen
toxicity-related chemotherapy modifcation
TP53
TP53 mutation status
TP53-mutaties
TP53-veranderingen
TPK cohort
TPP
traankliertumoren
trabectedin
trabectedin plus radiotherapy
TRACERx
trametinib
tranplantation-ineligible MCL patients
transarterial chemoembolization
transarterial hepatic chemoembolization
transarteriële chemo-embolisatie
transdermaal fentanyl
transdermale toediening
transformation
transformation to SCLC
transgender people
transgenders
transorale robotische chirurgie
transplant-ineligible multiple myeloma
transplantation for older leukemia patients
TRAP study
TRASTS study
trastuzumab
trastuzumab deruxtecan
trastuzumab duocarmazine
trastuzumab emtansine
trastuzumab plus paclitaxel
trastuzumab-resistant HER2-positive breast cancer
treatment
treatment and outcome in Germany
treatment at specialized cancer centers
treatment failure
treatment in Europe
treatment interruption
treatment patterns
treatment recommendations
treatment-emergent small-cell neuroendocrine prostate cancer
treatment-free survival
treatment-related cardiotoxicity
treatment-related incidence of diseases of the circulatory system
treatment-related toxicity
treatments for advanced NSCLC
trebananib
tremelimumab
tremelimumab after platinum
TREnd-studie
trends
trends 2005-2015
trends 2008-2014
trends of cancer in children and adolescents
treosulfan-fludarabine conditioning
trial effect
TRIAS study
TRIBE
TRIBE and TRIBE2 pooled analysis
TRICOLORE-studie
trilaciclib
trimodal therapy
TRINOVA-1
triple negatieve borstkanker
triple negative borstkanker
triple negative breast cancer
triple negative mammacarcinoom
triple-class refractory multiple myeloma
triple-negatief mammacarcinoom
triple-negative borstkanker
triple-negative breast cancer
triple-negative mammacarcinoom
triptorelin
TROG 03.01-studie
TROG 99.03 study
trombo-embolie
trombocyt lymfocyt ratio
TRT
TSC
TSCC
Tsjernobyl
TSP-1
TSR
TTAC
TTC
TTF
TTFields
TTP
tubaligatie
Tubo-ovarian high-grade serous carcinoma
tubulysines
tucatinib
tucidinostat
tumor budding
tumor mutation burden
tumor mutational burden
tumor regrowth between surgery and radiotherapy
tumor suppressor
tumor treating fields therapy
tumor-DNA
tumor-geassocieerde neutrofielen
tumor-immuuntolerantie
tumor-infiltrating lymphocytes
tumor-stroma ratio
TUMORAPA study
tumorgraad
tumorgrootte
tumorinfiltrerende lymfocyten
tumoronderdrukkers
tumorpredispositiesyndroom
tumorsubtypen
tv kijken
TVU
tweede kanker
tweede maligne neoplasmen
tweede maligniteit
tweede mammacarcinoom
tweede primaire maligniteit
tweejaaars-overleving
tweevoudige HER2-blokkade
twice versus once daily radiotherapy for SCLC
two weeks on
type 1-diabetes
type 2 diabetes
type and timing of menopausal hormone therapy
tyrosinekinaseremmers
tyrosyl-DNA fosfodiësterase 1
U.S. papillary thyroid cancer incidence trends
UADT-carcinomen
UATD-kanker
UBC
UC
UCB
UCC
UDON
UGT1A1 genotype
uHCC
UIP-ADC
UK Flexible Sigmoidoscopy Screening Trial
UK IMPORT LOW studie
UK Million Women Study
UK MRC OE05-studie
ulocuplumab
ultrasonografie
ultrasonography
ultrasonography findings
ultrasound
umbralisib
umbrella protocol
UMRD
underestimation of invasive breast cancer
unexpected uterine cancer
unilateral retinoblastoma
United Kingdom Women’s Cohort Study
UNITY-NHL study
unknown primary lesions
unmet needs
unnecerssary adjuvant chemotherapy in breast cancer
unplanned 30-day readmission
unplanned reoperation
unrelated donor hematopoïetische celtransplantatie
unresectable intrahepatic cholangiocarcinoma
unresectable malignant pleural mesothelioma
unresectable stage IIIA B NSCLC
untreated multiple myeloma
uPAR
update MONALEESA-2
Update WECARE-studie
updated analysis KEYNOTE-024
upfront bortezomib
upper tract urothelial cancer
upper tract urothelial carcinoma
upper-tract urothelial carcinoma
urbanisatiegraad
urinaire bijwerkingen
urinary cytokine profile to predict response
urine DNA hypermethylation signatures
urine tumor DNA
urinetest
urineweginfectie
urotheelcarcinoom
urotheelcarcinoom van de blaas
urotheliaal blaascarcinoom
urotheliaal carcinoom
urothelial bladder carcinoma
urothelial cancer diagnosis
urothelial carcinoma
USC
use of BRCA-testing
use of fertility drugs
USPSTF recommendation
uterine corpus cancer incidence and survival trends
uterine leiomyosarcoma
uteruscarcinoom
UTUC
uveaal melanoom
uveaalmelanoom
V600E V600K BRAF-mutant melanoma
V600E-BRAF mutated metastatic colorectal cancer
vaccin
vaccin mammacarcinoom
vaccinatie
vaginal brachytherapy plus chemotherapy
vaginal laser treatment
VAIN
Val600 BRAF-mutant melanoom
validation
VALOR-studie
valproaat
valproate and retinoic acid in combination with decitabine
vals positieve uitslag
variant histology
variation in surgery for DTC
varicella zoster virus vaccine
varying test positivity thresholds
Vasaloppet
vasectomie
vasectomy
VCE
VE-BASKET study
veeleisende patiënten
vegetarische voeding
VEGF
VEGF-behandeling
VEGFR-remmer
VEGFR-TKI
VEGFR-TKIs
VELIA GOG-3005 study
veliparib
VELVET
VELVET cohort 2
vemurafenib
vemurafenib and cometinib for BRAF-mutant melanoma
vemurafenib plus everolimus
venetoclax
venetoclax plus low-dose cytarabine
venetoclax-BR
veneuze trombo-embolie
venous thromboembolism
verbal memory
verf
verhoogd bloedglucose
VeriStrat test
vermoeidheid
verpleegkundigen
vertebral fractures
verteerbaar koolhydraat
vertrouwen
verzadigd vet
vessel co-option
vestibular schwannoma
vestibular schwannomas
vetinname
vetrijke voeding
vetzuren
VGX-3100
video-assisted thoracoscopic surgery
VIN
vincristine
vinorelbine
VIOLA study
virotherapy
viscerale adipositas
visconsumptie
VITAL study
VITAL-studie
vitamin A
vitamin D
vitamin D binding protein
vitamin D levels
vitamin D supplement use
vitamin D3
vitamin K antagonists
vitamin supplements
vitamine B3
vitamine B6
vitamine D
vitamine D-spiegel
vitamine-inname
vitamins
vitiligo
Vivio
VIVROVAIRE I study
VLADI-studie
Vlagtwegge-Vlaardingen cohort
vlees
vleesconsumptie
vliegend personeel
vluchtige organische verbindingen
VMS
VOCs
voeding
voeding tijdens zwangerschap
voedingsgewoonten
voedingskwaliteit
voedingssupplementen
voedingsvezel
voice abnormalities
volasertib
volatile organic compounds
VOLFI study
VOLFI-studie
von gunten
von hippel-lindau
Von Willebrand Disease
voorspelling recidief
voorspelling ziektevrije overleving
vosaroxine
VR consolidation
VRD as induction prior to autoSCT
vroeg mammacarcinoom
vroege detectie
vroege detectie MBC
vroege menopauze
vroege resultaten COMPASS-studie
VS
VSCC
VTE
VTEs
vulvacarcinoom
vulvaire intra-epitheliale neoplasie
vulvaire intraepitheliale neoplasie
vulvaire lichen sclerosus
vulvar squamous cell carcinoma
vulvovaginal atrophy in breast cancer patients
VWF
wachttijd
Waldenström macroglobulinemia
Waldenstrom's macroglobulinemie
Waldenström’s macroglobulinemie
warfarine
warren
watch and wait
watch-and-wait
watchful waiting
WBI
WBM
WBRT
WD DDLS
WDTC
web-based symptom monitoring vs routine surveillance
WECARE-studie
weefseltype-agnostische gerichte therapie
weekly carboplatin and paclitaxel
weekly dose-dense chemotherapy
weekly KMP
weekly paclitaxel
weight cycling
weight loss
weight trajectories
wekedelensarcoom
wekedelensarcoom. STS
werkloosheid
werkzaamheid placebo
WES
wetenschappelijk wangedrag
WHI
WHI-CaD studie
WHI-DM
whole brain radiation
whole brain radiotherapy
whole-body MRI
whole-brain radiation therapy
whole-genome sequencing
WHR
wigresectie
Wilms tumor
Wilms' tumor
Wilms’ tumor
withdrawal of antiepileptics
WM
women's health initiative
Women's Health Initiative-Observational Study
Women’s Health Initiative
WSG-ADAPT studie
WT
WTB-HRM
WTC-responders
XELAVIRI study
XELOX FOLFOX vs LV 5-FU
xerostomia
XRT plus ADT
YAP
YKL-40
YM155
yoga
yogurt consumption
young adult ALL patients
younger versus older adults
zanubrutinib
ZAP-studie
zegelringcelcarcinoom
zelf-gerapporteerde vermoeidheid
zelf-onderzoek huid
zelf-test
ziekenhuisvolume
Ziekte van Castleman
Ziektevrije-overlevingsanalyse van ABCSG-18 studie
zinc-α2-glycoprotein
zittende leefstijl
ziv-aflibercept
zoledroninezuur
zonlicht
ZUMA-1 studie
ZUMA-1 trial
ZUMA-studie
ZW25
zwangerschap
zwangerschaps-geassocieerd mammacarcinoom
zwangerschapsuitkomsten
γ-glutamyltransferase